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Abstract 
The field of molecular imaging is constantly growing and evolving in order to provide the 
best possible healthcare for patients in various stages of disease and therapy. Molecular 
imaging aims to locate specific markers of disease by selectively targeting the markers of 
interest with high selectivity and visualizing the accumulation using external detection.  
The growth hormone secretagogue receptor-1a (GHS-R1a) has been shown to be involved in 
various important biological functions such as energy homeostasis and cardiac contractility. 
GHS-R1a has shown involvement in proliferation, migration and cell invasion of specific 
cancer subtypes. Therefore, targeting GHS-R1a is an important marker of different disease 
states and would be advantageous to selectively target for diagnostic and therapeutic 
purposes. 
This thesis will document the development of peptide-based molecular imaging agents 
capable of targeting GHS-R1a with high affinity designed off the structure of ghrelin, the 
endogenous ligand for GHS-R1a. 
Chapter 2 discusses the synthesis and evaluation of gallium-69/71 and gallium-68 labelled 
ghrelin(1-19) analogues. The first generation of ghrelin analogues was designed to detect 
GHS-R1a by positron emission tomography (PET). Chelation of gallium had a positive effect 
on binding affinity to GHS-R1a resulting in an IC50 comparable to natural ghrelin(1-28). 
Preclinical evaluation of HT1080/GHSR-1a xenografts showed higher SUVR values than the 
HT1080 xenograft with no GHS-R1a.  
Chapter 3 discusses the second generation of ghrelin analogues that were further truncated to 
eight amino acids. A structural activity study investigated residues 1, 3, 4, and 8 to determine 
whether amino acid substitutions produce the best binding affinity GHS-R1a. The optimized 
ghrelin analogue has 12-fold higher binding affinity to GHS-R1a than natural ghrelin. New 
radiochemical syntheses were reported for a 6-[18F]-fluoro-2-pentafluorophenylnaphthoate 
prosthetic group. The lead peptide analogue was radiolabelled in a 3% radiochemical yield 
and resulted in the first fluorine-18 labelled ghrelin(1-8) analogue with greater affinity to 
GHS-R1a. 
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The final chapter describes the effects of targeting GHS-R1a with a dimerized ghrelin(1-8) 
peptide. Dimerizing other peptide targeting entities has increased binding affinity to the 
target however, this is not the case found with ghrelin. The in vitro kinetics were evaluated 
using fluorescence microscopy in GHS-R1a expressing cells. 
All three chapters discuss the systematic modification of an endogenous peptide ligand into a 
high affinity, PET imaging agent through classical methods of peptide modification and 
radiochemistry.  
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Chapter 1  
1 Introduction 
1.1 Peptides and Molecular Imaging 
The complexity of all living systems is a daunting task to understand. Yet, when broken 
down into fundamental building blocks, the complexity of these systems appears to be an 
eloquent work of art. One fundamental building block of all complex living systems is 
peptides. Found in all living systems, peptides are diverse naturally occurring compounds 
responsible for many biological functions. They are capable of acting as 
neurotransmitters, growth factors or antimicrobials, as well as facilitating cell-to-cell 
communication and ion-channel regulation, to name only a few.  Peptides fit a 
specialized niche between the two molecular weight extremes of small molecules and 
proteins. They are able to combine the benefits of small molecules, such as low cost, 
membrane permeability and metabolic stability, with target specificity and high potency 
seen in proteins and antibodies. More importantly, peptides and their endogenous 
receptors have been implicated in disease states such as oncology, metabolic disorders 
and cardiovascular disease.1 
 
Natural peptides, composed entirely of natural components, are known to have a 
relatively short in vivo half-life and are readily metabolized by endo- and exo- peptidases. 
Fortunately, peptides can be easily manipulated to increase in vivo stability, membrane 
permeability and target selectivity using well-known methods. These methods have been 
applied to many natural peptides to target their endogenous receptors for diagnosis and 
therapeutic applications. In order to detect these natural peptides externally, they must be 
modified to contain a signalling source capable of being detected with the various 
molecular imaging modalities. Molecular imaging modalities commonly used in both 
preclinical and clinical settings are positron emission tomography (PET), single-photon 
emission computed tomography (SPECT), magnetic resonance imaging (MRI), 
ultrasound (US) and optical imaging (OI). Each modality has their own strengths and 
weaknesses with respect to imaging sensitivity and spatial resolution.2 In comparison to 
2 
 
the other modalities, PET has attractive attributes due to its high image sensitivity and 
requires radionuclides as a signalling source that have suitable attributes for diagnostic 
molecular imaging. Optical imaging is another imaging modality with high image 
sensitivity that doesn’t require a radioactive signalling source. The commonly used 
methods to incorporate PET and OI signalling sources into natural peptides, as well as the 
many approaches to modifying these peptides for improved in vivo pharmacokinetics will 
be outlined. 
1.2 Suitable Signaling Sources for PET and OI 
Peptide-based targeting entities are a versatile class of radiopharmaceuticals able to 
selectively target receptors within the human body, allowing for a disease to be detected, 
staged, or treated. External monitoring of radiolabelled targeting entities can be achieved 
via a sensitive molecular imaging modality currently used in nuclear medicine: PET.1 
PET has slowly gained popularity since its discovery in the 1960’s and has since become 
clinically acceptable. This modality requires a radionuclide to emit photons in the form of 
radiation, which can then be externally detected and processed into an image. PET 
requires radionuclides that decay via positron emission (Table 1.1). Once a positron is 
ejected from the nucleus, it travels a short distance before colliding with an electron. An 
annihilation event produces two 511 keV gamma rays emitted at a coincidence angle of 
180o and are simultaneously detected by two scintillation detectors (Figure 1.1).  
Table 1.1 Common PET radionuclides and half-lives. 
Isotope Half-life 
Carbon-11 20.4 m 
Copper-64 12.7 h 
Fluorine-18 109.7 m 
Gallium-68 68 m 
Nitrogen-13 9.96 m 
Oxygen-15 2.07 m 
Yttrium-86 14.7 m 
Zirconium-89 3.27 d 
3 
 
 
Figure 1.1 Depiction of an annihilation event within a PET Scanner. A β+ emitting radioisotope ejects a 
positron from its nucleus that meets an electron. Upon contact, the positron and electron undergo an 
annihilation event resulting in two 511 keV gamma rays being emitted approximately 180° apart. The 
emitted gamma rays are detected by a ring of scintillation detectors and further processed into a PET 
image. 
There are a number of radioisotopes that have applications in PET imaging. The most 
prevalent PET radioisotope, as well as the most important isotope in the 
radiopharmaceutical industry due to 2-deoxy-2’-fluoro-D-glucose (FGD), is fluorine-18 
(18F). F-18 is a cyclotron-produced radioisotope made from an oxygen-18 (18O) enriched 
target. The half-life of 110 minutes allows the isotope to be made off-site and shipped to 
facilities for use. Most commonly the radioisotope is shipped as synthesized [18F]-FDG. 
[18F]-FDG is used to monitor glucose metabolism and has gained popularity in the field 
of oncology due to the high metabolic activity observed in most types of malignant 
tumours. [18F]-FDG can also be used to monitor treatment regimens. Unfortunately, [18F]-
FDG uptake is not specific to tumours, but is also taken up by areas of natural high 
glucose metabolism such as the brain and kidney. Therefore, there is interest in 
developing a peptide-based targeting agent that bears fluorine-18 and can achieve higher 
specificity for its target. Due to the small atomic radius of fluorine, it can be integrated 
into many biomolecules without greatly affecting the binding region. Fluorine-18 has 
been integrated into most natural peptides such as somatostatin, α-melanocyte stimulating 
hormone (MSH), neurotensin, RGD, and bombesin.3, 4 In addition to fluorine, carbon, 
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which is known for its ability to form a vast number of compounds, also has a radioactive 
isotope, carbon-11 (11C). Carbon-11 has a short half-life of 20.4 minutes and can be 
incorporated into many molecules resulting in a negligible isotope effect. Due to its half-
life, it is most suited for short-lived radiopharmaceuticals in facilities that have access to 
an in-house cyclotron. Gallium-68 (68Ga) is an additional radiometal with a 68-minute 
half-life that is gaining popularity as a PET isotope. The parent isotope, germanium-68 
(68Ge), has a 271-day half-life, allowing it to be packaged into a 68Ge/68Ga generator that 
functions similarly to the 99Mo/99mTc generators. Since germanium-68 has a long half-
life, these generators can last over a year before being replaced. The most common use 
for gallium-68 is DOTA-TOC, a peptide-based imaging agent used to target somatostatin 
receptors in neuroendocrine tumours.5,6  
The choice of radionuclide is dependent on the half-life, availability, method of 
incorporation, and method of radioactive decay.  The half-life must be long enough to 
withstand synthesis, administration and distribution of the probe while maintaining 
enough radioactivity to be detectable by the imaging modality. The availability and 
proximity of a cyclotron limits the choice of radionuclides to generator-produced isotopes 
that can be produced on-site. There are different methods for incorporating a radioisotope 
that will be mentioned later on. The positron emission energy is an important aspect of 
PET imaging. Isotopes with lower positron emission energy, usually measured in electron 
volts (eV), produce images with higher resolution than those with higher positron 
emission energy. 
On the other hand, optical imaging is a low cost, high sensitivity and facile method of 
molecular imaging. In order to successfully synthesize an optical imaging agent, a 
targeting entity must contain a fluorophore signaling source for external detection.7 
Fluorophores used in the early development of optical imaging emitted photons of 300 to 
600 nm after excitation by an external source. Unfortunately, due to the many structures 
within a cell, the scattering and absorption of the shorter photons in the visible region 
limited the use of these fluorophores for in vivo applications. Longer wavelengths in the 
near-infrared (NIR) region of 600 to 900 nm are less likely to be absorbed and scattered 
by the structures within cells. This allows photons emitted in the NIR region to penetrate 
5 
 
tissue several centimeters deep.8 These longer wavelengths are capable of penetrating 
tissues and expand the use of fluorescence to in vivo applications that were not previously 
applicable.9 
With respect to oncology, optical imaging and the other molecular imaging modalities 
have made large advancements with respect to tumour detection, staging and treatment 
using targeted imaging modalities, such as peptides. When it comes to removal of 
cancerous tissues by surgery, translation of the information gained from a PET, SPECT 
or MRI image can be difficult to apply to the operation field.10 This makes complete 
resection of a tumour difficult and leads to a chance of disease reoccurrence.11 NIR-OI 
has been used to effectively address this issue. NIR-OI has the adequate image resolution 
and tissue visualization required for real-time fluorescence imaging that can be used to 
distinguish between cancerous and healthy tissue not apparent to the naked eye.10 Using 
this technique, surgeons can effectively visualize and remove the cancerous tissue leaving 
all healthy tissues intact and limiting the chance of disease reoccurrence. One example of 
this was evaluated in colonic dysplasia using an octapeptide, QPIHPNNM, bearing a NIR 
Cyanine-5.5 (Cy-5.5) dye.12 Using real time fluorescence imaging, NIR images were 
collected endoscopically in mice with colonic dysplasia. There was significant contrast 
between areas of dysplasia and normal colonic mucosa not visualized in the white light 
image.12 
1.3 Methods for Adding Radionuclides to Peptides 
In an ideal situation, a radionuclide would be added into a natural peptide sequence 
without changing the biological behaviour of the peptide, such as binding to a protein 
receptor. This is generally not the case and different methods of incorporation have 
varying levels of effect on binding affinity. Addition of a radionuclide can be achieved in 
four general ways: pendant labelling, integrated labelling, prosthetic group incorporation, 
or direct labelling (Figure 1.2). Most commonly, radiometals are attached to peptides 
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through pendant labelling. This method requires a bifunctional metal chelator to be
 
Figure 1.2 Various methods for introducing a radioisotope into a peptide sequence: pendant labelling, 
prosthetic group labelling, direct labelling and integrated labelling. 
appended to the peptide sequence; bifunctional in that the chelator can be attached to the 
peptide and also can coordinate a metal. Cyclic chelators, such as 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and 1,4,7-triazacyclononane-
1,4,7-trisacetic acid (NOTA), are used for radiometals including 67Ga, 68Ga, and 64Cu. 
Acyclic multidentate chelators such as diethylene triamine pentaacetic acid (DTPA) and 
6-hydrazinonicotinic acid (HYNIC) analogues, can also be used (Figure 1.3).13-15 It is 
challenging to incorporate these chelators into a peptide without having a detrimental 
effect upon the ability of the peptide to target a protein receptor. Due to the size of the 
chelation moiety, it must be located away from the binding region within the sequence to 
avoid steric interactions or other undesirable non-covalent interactions with the receptor. 
To achieve this distance, the chelators are often placed at the N- or C-terminus of the 
peptide, on an amino acid side chain such as lysine, or following an aliphatic spacer. This 
additional linkage increases the molecular weight of the peptide and is therefore not an 
ideal way to radiolabel small targeting peptides. Integrated labelling, on the other hand, 
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aims to hide a radiometal within the targeting peptide resulting in the metal being a key 
structural component of the peptide. One approach to this is to have the metal induce 
secondary structure formation, such as cyclization of the peptide, around the isotope. 
Examples of this method are used for cyclization of natural peptides such as 
gonadotropin-releasing hormone and somatostatin during technetium chelation.16-18 This 
mode of concealing the isotope within the peptide would ideally have little effect on the 
binding affinity of the targeting entity. The third method for radiolabelling a peptide is 
the prosthetic group labelling approach, which is ideal for radionuclides with lower 
atomic mass, such as 18F and 11C. A small molecule is developed as a precursor for 
radiolabelling that can be easily incorporated into an amino acid side chain in one or two 
synthetic steps. This method often includes purification and deprotection steps to achieve 
a final pure radiolabelled peptide. In order to retain radiochemical yield, time efficient 
and high yielding reactions must be used for every synthetic step, especially when 
working with short-lived radionuclides. The most common synthetic approaches for 
incorporating fluorine-18 into a prosthetic group are nucleophilic acyl substitution and 
nucleophilic aromatic substitution.19,20 The development of bioorthogonal chemistry has 
led to high yielding, high specificity reactions capable of incorporating a radiolabelled 
prosthetic group into a natural peptide sequence. These reactions include Staudinger 
ligation, azide-alkyne Huisgen cycloaddition, and inverse demand Diels-Alder 
cycloadditions.21, 22 Prosthetic group labelling has led to increases in reaction rates and 
yields; however, the numerous synthetic and purification steps required are detrimental to 
overall radiochemical yields. In order to further improve radiochemical yields, a direct 
labelling approach has become increasingly popular. This method places a radionuclide 
on a modified amino acid side chain using a simple one-step reaction. However, the main 
challenge with this method is to obtain site specific radiolabelling without disrupting the 
functionality of the side chains, which may contain amines, carboxylic acids or amides 
that are found in most peptide sequences. The direct labelling method has had varying 
success with respect to radiochemical yields, with a variety of approaches being 
described, including: di-tert-butylsilyl functionalized bombesin analogues, one-step 
nucleophilic aromatic substitution with a trimethylammonium leaving group, chelation of 
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[18F] aluminium fluoride, and nucleophilic aromatic substitution on an aromatic ring with 
a nitro leaving group containing withdrawing groups in ortho and para positions. 23-25 
 
Figure 1.3 Common cyclic and acyclic chelators capable of chelating various radiometals: (A) 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), (B) 1,4,7-triazacyclononane-1,4,7,-trisacetic acid 
(NOTA), (C) diethylenetriamine-N,N,N’,N’,N’’’-pentaacetic acid (DTPA), (D) 6-hydrozinonicotinic acid 
(HYNIC). 
1.4 Modifying Radiolabelled Peptides for Improved In Vivo 
Stability and Target Affinity 
Peptides as targeting vectors offer many advantages with respect to other molecules, but 
of course come with their own set of limitations. Natural peptides are known to have poor 
oral bioavailability as well as low metabolic stability in vivo. Poor oral bioavailability is 
less of a concern for imaging agents as opposed to therapeutic drugs, since 
radiopharmaceuticals are typically administered intravenously, while poor metabolic 
stability can be overcome using structural modifications designed to inhibit enzymatic 
degradation. Peptides are often degradade by exopeptidases, enzymes that specifically 
hydrolyze the C- and N-termini of a linear peptide. In order to resist exopeptidase 
degradation, the functionality of the termini can be altered. The simplest approach is to 
have the C-terminus synthesized as an amide and the N-terminus acetylated. Degradation 
by exopeptidases can also be countered by head-to-tail cyclization, which removes the 
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termini completely. Endopeptidases that are capable of hydrolyzing peptide bonds within 
a peptide sequence are also of concern. Endopeptidases are only able to recognize natural 
L-amino acids; therefore replacing positions of hydrolysis with D-amino acid or unnatural 
amino acid residues causes the peptides to become unrecognizable to the peptidase. 
Contrary to the standard alpha-(α) amino acids, unnatural beta-(β) and gamma-(γ) amino 
acid substitutions have the ability to arrange amino acid side chains into specific three-
dimensional conformations, tending to form helical and pleated sheet-like structural 
motifs (Figure 1.4).26 These small structural modifications result in greater in vivo 
stability, while the peptide sequence remains virtually unchanged, allowing it to maintain 
target affinity.   
 
Figure 1.4 Stereochemistry of natural L-amino acids as well as unnatural D-amino acids, α-amino acids, 
β-amino acids, and γ-amino acids. R represents the applicable amino acid side chains. 
A more complex method to increasing in vivo stability is to employ the pseudo-peptide 
approach. Pseudo-peptides resemble the natural peptide structure, but contain chemical 
modifications to the backbone that render them unrecognizable to peptidases. Some 
examples include peptoids, aza-peptides, and amide-bond surrogates as shown in Figure 
1.5. Peptoids, also known as N-substituted glycine’s, have not only been found to 
increase peptide stability but also increase cell permeability by 20-fold compared to the 
analogous peptide sequence. Attachment of the peptide side chains to the backbone 
nitrogen eliminates the polar N-H bond causing an increase in lipophilicity, and in turn, 
an increase in cell permeability.26 Aza-peptides, which replace one or more alpha-carbons 
with a nitrogen atom, have been shown to result in a loss of stereogenicity and reduced 
flexibility by replacing the rotatable αC-C(O) bond with a more rigid αN-C(O) bond. 
COO
R
H3N H
COO
R
H NH3
L-amino acid D-amino acid
α-amino acid β2-amino acid γ-amino acid
H3N CO2-
R
CO2-
R
H3N
CO2-H3N
R
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This reduction in flexibility has shown turn-inducing capabilities when the aza-residue is 
placed in the i+1 or i+2 position favouring beta-turn conformations.27, 28 Amide bond 
surrogates are designed to mimic the geometric structure of a peptide bond as well as 
maintaining the positioning of side chains. Well known amide bond surrogates include 
thioamides, esters, alkenes and fluoroalkenes but could be more detrimental to in vivo 
stability. Thioamides are the most closely related surrogate to the standard amide bond 
based on its number of atoms and the arrangement of valence electrons. Sulphur is a poor 
hydrogen bond acceptor compared to oxygen, but the nitrogen proton maintains hydrogen 
bond donation when part of a thioamide. Ester substitutions, although geometrically 
similar to amide bonds, are not able to undergo hydrogen bond donation and act as poor 
hydrogen bond acceptors, resulting in poor stability of secondary structure. More 
importantly, esters are vulnerable to hydrolysis in vivo and are therefore not an attractive 
surrogate. Alkene surrogates, on the other hand, completely lack a heteroatom capable of 
non-covalent interactions but remain a popular peptide bond substitution due to their 
ability to accurately mimic rigidity, bond angle, and bond length. It must be noted that 
alkenes are susceptible to isomerization, oxidation and chemical liability in vivo; 
however, they have been successfully incorporated into natural peptides such as the 
tripeptide RGD and C-X-C chemokine receptor 4 CXCR4.29, 30 Heterocyclic moieties, 
such as 1,2,4-oxadiazole, 1,3,4-oxadiazole, 1,2,4-triazole and 1,2,3-triazole are also used 
as amide bond mimics.31, 32 A variety of strategies can be used to increase in vivo stability 
of natural peptides ranging from simply exchanging L and D amino acids to more 
complex substitution of pseudo-peptides. Each approach is accompanied by its own 
advantages and disadvantages dependent on the natural peptide, target, and mode of 
action. Finding the optimal peptide analogue can require various permutations in peptide 
structure and the preparation and analysis of large libraries of peptide analogues is 
advantageous for discovering the most suitable candidate. 
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Figure 1.5 Various backbone modifications to alter in vivo stability of natural peptides. R represents 
various amino acid side chains. 
Much of the development of receptor targeting peptides has focused on receptor agonists. 
Agonists are known to possess high binding affinities for their receptors that trigger 
internalization of the ligand-receptor complex. It was rationalized that the internalization 
and accumulation of the radioligand in the cell over time would lead to better target-to-
background ratios and overall a better radiopharmaceutical. It wasn’t until the late 1990’s 
that attention began to shift from agonists to potent antagonists. Antagonists are capable 
of binding orthosteric and/or allosteric sites on a receptor without eliciting a biological 
response and therefore, are not internalized, as agonists would be. Comparative studies 
show that antagonists have better chemical stability and longer duration of action than an 
agonist as well as binding can persist up to 8 days.33 Many well-known receptor targets 
have been investigated for antagonist ligands and have resulted in improved stability and 
in vivo stability.  
1.5 Modifying Natural Peptides for Improved 
Pharmacokinetics 
The success of any pharmaceutical agent is dependent on its pharmacokinetics. 
Undesirable pharmacokinetics leads to faster degradation and clearance of the 
pharmaceutical. Elimination of radiolabelled peptides occurs rapidly and mainly by renal 
excretion. Rapid excretion of such molecules is advantageous for creating high quality 
images with low background activity but unfortunately radiolabelled peptides are often 
trapped in the kidneys due to tubular reabsorption.34 The exact mechanism of this process 
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is not completely understood but studies suggest that megalin, a multiligand receptor, 
plays an important role. Retention in the kidneys not only causes high background noise, 
but also delivers high radiation doses. Renal uptake of various radiolabelled peptides has 
been reduced by co-administration of cationic amino acids, such as lysine and arginine, 
yet these methods come with undesired physical effects such as nausea and 
nephrotoxicity.35, 36 Reducing renal uptake has also been achieved by co-administration 
of albumin, a megalin substrate.35 
1.6 Increasing Receptor Affinity using Multimerization 
In 1998, Mammen introduced the theoretical framework for multivalency by stating that 
biological species can have multiple simultaneous interactions with ligands or receptors 
at any one time.37 Mammen also stated that polyvalency creates stronger interactions 
between biological entities.37 Building off this theoretical framework, peptide multimers 
were hypothesized as a viable method to increase affinity of any monomeric targeting 
entity. Two types of multimers can exist; homomultimers or heteromultimers (Figure 
1.6). Homomultimers contain two or more copies of identical targeting entities in one 
compound, for example, two copies of RGD tethered together.38 In contrast, 
heteromultimers contain two or more different targeting entities in one compound, for 
example bombesin and RGD.39 
 
Figure 1.6 Pictorial representation of receptor targeting with homomultimers and 
heteromultimers. 
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Peptide homodimers, or homomultimers have been well documented to obtain better 
binding affinity to biological targets than their monomeric counterparts. The increased 
binding affinity is caused by higher local concentration of the targeting entity around the 
receptor. More copies of the targeting entity in the immediate surroundings of the 
receptor creates a shielding effect that reduces the competition of other endogenous 
ligands for the receptor.40 Therefore, after the receptor dissociates from the bound ligand, 
it is more likely to bind another copy of the targeting entity in the homodimer or 
homomultimer. Extensive studies have been done on multimerization using RGD, an 
integrin αvβ3 targeting peptide, by synthesizing a homodimer, homotetramer and 
homooctamer of the peptide and integrated radionuclides for in vitro and in vivo 
detection. The binding affinity was directly dependent on the number of copies of RGD 
in each compound. The highest binding affinity was observed with the homooctamer, 
followed by the homotetramer, homodimer and finally the monomer.41 
The basis for developing heteromultimers is based on the fact that the cell surfaces of 
diseased cells expression many different receptor subtypes. Integrating two targeting 
entities into one molecule creates a dual targeting approach. Studies have shown that 
heterodimers a bombesin/RGD result in better imaging results when compared to the 
monomeric counterparts.42 This phenomenon is caused by an increase in overall receptor 
density. When targeting two receptor subtypes, the total available receptor binding sites 
increases to the sum of both receptors, where as monomeric targeting entities have less 
available binding sites in comparison.40 
Multimerization is still a new concept in the area on molecular imaging but initial 
research supports the development of homomultimers and heteromultimers to improve 
binding affinity of monomeric peptide targeting entities. The design of these peptides can 
be difficult without a thorough understanding of the receptor expression. Various 
analogues of dimers may be necessary to optimize the molecular space between targeting 
entities and the overall three-dimensional conformation of the multimeric compound.43 
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1.7 Growth Hormone Secretagogue Receptor-1a and 
Ghrelin 
Ghrelin is found within the growth hormone secretagogue family that was previously 
made up of small synthetic molecules known as growth hormone releasing peptides 
(GHRP).44 Secretagogues stimulate the release of hormones, mainly growth hormone, 
from the pituitary by activating a G-protein coupled receptor, GHS-R1a. In 1999, Kojima 
was the first to discover the endogenous ligand for GHS-R1a that remained unknown for 
so long. It was discovered that ghrelin stimulates the release of growth hormone without 
affecting any other hormone release. The purified ligand resulted in a 28 amino acid 
peptide containing an n-octanoylated serine at residue 3. This ligand was name ghrelin 
from the Proto-Indo-European word “ghre” meaning grow.45 The octanoylation observed 
in human ghrelin has not been observed previously in peptide modifications, thus this 
suggests that this modification happens in a post-translational manner. More 
interestingly, there is no structural homology between ghrelin and the synthetic GHSs 
previously discovered.  Ghrelin also has no sequence homology to any known 
biologically active peptides.45 
 
Figure 1.7 The structure of natural human ghrelin. 
Immediately after the discovery of ghrelin, the scientific community became very excited 
to understand the critical structural features involved in the ghrelin/GHS-R1a interaction. 
A mere four months after the discovery of the ghrelin sequence, the first modified ghrelin 
analogues were published. This study began investigating the role of the octanoylated 
serine side chain by introducing various other aliphatic and aromatic acids within that 
position, the biological importance of the ester linkage at the serine side chain by 
replacing this linkage with an amide bond and finally, the minimum human ghrelin 
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segment capable of activating GHS-R1a by synthesizing various truncated analogues 
(Table 1.2).46  
Replacing the octanoylated side chain with hydrophobic acids of comparable size, such 
as unsaturated 2,4,6-octatrienoic acid or 11-undecanoic acid, resulted in compounds with 
comparable affinity to GHS-R1a. Although incorporation of amino and amido groups 
within the side chain resulted in detrimental binding affinity. Replacement of the ester 
linkage with an amide linkage had little effect on binding affinity resulted in a more 
stable linkage that is not susceptible to esterases or acyl migration. Finally, synthesis of 
various truncated ghrelin analogues from ghrelin(1-23) to ghrelin(1-4) were synthesized 
and determined that the first 5 N-terminal amino acids are required to not only bind to 
GHS-R1a but also to elicit effective activation of GHS-R1a.46 A similar study was 
published in 2001 by Mutsumoto and supported the previous findings.47 
Table 1.2 Published Modified Ghrelin Analogues. 
Ghrelin Analogue Residue 3 Literature 
IC50 (nM) 
Ref. 
Ghrelin (1-28) Ser(octanoyl) 0.25 42 
Ghrelin(1-28) Ser(2,4,6-octatrienoic acid) 0.98 42 
Ghrelin(1-28) Ser(11-undecanoic acid) 0.12 42 
Ghrelin(1-28) Ser((CH2)6NH2) >2000 42 
Ghrelin(1-28) Ser((CH2)2CO-NH-(CH2)2CH3) 1020 42 
Ghrelin(1-28) Dpr(octanoyl) 0.42 42 
Ghrelin(1-23) Ser(octanoyl) 0.16 42 
Ghrelin(1-5) Ser(octanoyl) 55 42 
Ghrelin(1-4) Ser(octanoyl) 889 42 
The role of ghrelin is well known to control growth hormone release, metabolism, 
appetite and insulin secretion but interestingly, ghrelin has been shown more involvement 
in the various stages of cancer such as cell migration, proliferation and apoptosis.48 From 
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as early as 2001, the presence of ghrelin production has been noted in many cancer 
subtypes such as adrenocortical, breast, colorectal, endocrine pancreatic, endometrial, 
gastric, lung, ovarian, pituitary, prostate, renal, and testicular cancers.49-57 
Recently, a fluorescent-ghrelin(1-18) analogue was developed and was able to distinguish 
prostate cancer from benign hyperplasia in ex vivo prostate tissue (Figure 1.7).58 
Additionally, this optical agent was investigated for its ability to image the heart and may 
be useful for the imaging of cardiac myopathy, a complication of diabetes.59 
Recently, a fluorescent-ghrelin(1-18) analogue was developed and was able to distinguish 
prostate cancer from benign hyperplasia in ex vivo prostate tissue (Figure 1.7).52 
Additionally, this optical agent was investigated for its ability to image the heart and may 
be useful for the imaging of cardiac myopathy, a complication of diabetes.53  
Two approaches to the radiolabelling of ghrelin have been explored. The first approach is 
the classical method of adding a metal chelator pendant to the peptide analogues at the C-
terminus via a lysine residue. In one instance, a DOTA conjugated ghrelin(1-19), which 
also contained a diaminopropanoic acid residue in position three, was radiolabelled with 
gallium-68 for use as a PET imaging agent and the gallium-69/71 variant was determined 
to have an IC50 of 9.1 nM for the GHSR.60 In another instance, a monodentate isocyanide 
ligand conjugated ghrelin(1-6) was radiolabelled with technetium-99m and determined to 
have an IC50 of 45 nM for GHSR.61 The second approach is an integrated design whereby 
the radioisotope is attached as part of a lipophilic side chain, replacing the octanoyl side 
chain of native ghrelin. Fluorine-containing side chains, both in the form of an aliphatic 
chain and as an aromatic entity, have been reported and the addition of a bulky fluoro-
napthyl group appears the most promising to date for eventual use as a fluorine-18 
labelled ghrelin analogue.62 In addition, a side chain containing a rhenium 
cyclopentadienyl tricarbonyl group has also been discovered to have GHSR affinity and 
is a unique discovery in that it is a rare example where an organometallic species is a key 
recognition element for a peptide-receptor interaction.63   
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1.8 Summary 
This thesis will document the development of human ghrelin from 28 amino acids, to 19 
amino acids and subsequently to 8 amino acids while maintaining affinity to GHS-R1a. 
During these truncations, optical dyes and radioisotopes have been integrated into various 
positions of the peptide sequence without detriment effects on affinity and enabling these 
peptide to visualize GHS-R1a using optical imaging (OI) or PET.  Chapter 2 will cover 
the first generation ghrelin(1-19) analogue bearing gallium-68 and the evaluation of this 
probe in preclinical studies. Chapter 3 will then cover the second generation of ghrelin(1-
8) analogues including an extensive structural activity study followed by optimization of 
fluorine-18 for future use in preclinical PET studies. Chapter 4 will investigate the 
possible multimerization of  a ghrelin(1-8) analogue into ghrelin(1-10) bearing a near-
infrared dye, cyanine-5. Chapter 5 will draw together all aspects of this thesis and 
summarize the strengths and weaknesses of ghrelin as an imaging agent capable of 
targeting GHS-R1a.  
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Chapter 2 
2 Development of a Novel [68Ga]-Ghrelin Analogue for 
PET Imaging of GHS-R1a 
2.1 Introduction 
The endogenous ligand for the growth hormone secretagogue receptor (GHS-R) was 
discovered in 1999 by Kojima et al. and subsequently named ghrelin.1 This 28 amino 
acid natural peptide hormone (Figure 2.1, 2.1) was found to possess a unique post-
translational modification that is not commonly seen in other peptide hormones. Through 
the action of ghrelin-O-acyltransferase, natural human ghrelin contains an n-octanoylated 
serine at residue 3 that has been found to be essential for its affinity and specificity to 
GHS-R. The highest concentration of ghrelin can be found in the stomach and this 
peptide is responsible for a diverse area of functions. Its primary role is to regulate 
growth hormone (GH) release but it has also shown to have stimulatory effects on 
appetite, gastric acid secretion, adiposity and gut motility.2  
 
Figure 2.1 . Amino acid sequence of natural human ghrelin (2.1) and des-acyl ghrelin (2.2) with the 
corresponding IC50 for GHS-R1a, as determined.by a competitive binding assay with HEK293 cells stably 
transfected with GHS-R1a. 
The GHS-R is present in two isoforms, types 1a and 1b. GHS-R1a is a 366 amino acid 
polypeptide and G-protein coupled receptor (GPCR) containing seven transmembrane 
domains. The third transmembrane domain has been recognized as the ligand-receptor 
binding pocket for human ghrelin. On the other hand, GHS-R1b is a 5-transmembrane 
receptor that has no binding affinity to human ghrelin and is not known to exhibit any 
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biological functions.3 Therefore, GHS-R1a has been labelled the “ghrelin receptor”. The 
ghrelin receptor can be found at low concentrations in various tissues such as human 
brain, kidney, cardiovascular system and prostate.2, 4  
In addition to regulating the growth and differentiation of normal tissues, the GHS-R1a 
has been shown to play important roles in proliferation, apoptosis, cell invasion and 
migration associated with cancer progression.5-10 More specifically, GHS-R1a has been 
found to be differentially expressed in prostate, breast, ovarian, testicular and intestinal 
carcinomas when compared to healthy tissue.11-14 By exploiting the specificity of ghrelin 
to its endogenous receptor, it has been proposed that ghrelin can be used to locate these 
various carcinomas using molecular imaging.15  
Within the literature, structure-activity studies of ghrelin have been thoroughly 
described.15-20 These studies have revealed that the n-octanoylated serine side chain is 
crucial for receptor interaction. The half maximal inhibitory concentration (IC50) of 
natural ghrelin (2.1) for GHS-R1a has been reported as low as 0.25 nM and by simply 
removing the octanoylated modification, resulting in des-acyl ghrelin (Figure 2.1, 2.2), 
the IC50 increases to >10 µM.17 Truncation at the C-terminal end of ghrelin retained 
affinity to GHS-R1a, suggesting the N-terminal portion is more important for receptor 
interactions. Truncated analogues containing the octanoylated serine such as ghrelin (1-
14) and ghrelin (1-5) resulted in respectable IC50’s of 9.6 nM and 55 nM respectively.17 
Lu, et al. synthesized a ghrelin (1-19) analogue bearing a fluorescein dye at lysine19 in 
order to optically image human ex vivo prostate tissue ranging from normal, benign 
hyperplasia, prostate interneoplasia and cancerous tissue. This modification to ghrelin 
resulted in an IC50 of 9.5 nM. Association of fluorescein-ghrelin (1-19) was found to be 
4.7 times higher in cancerous prostate tissue than normal and benign hyperplasia.20 This 
was the first example highlighting ghrelin’s potential as an imaging probe for prostate 
cancer diagnosis and possibly for detection of metastatic disease. The ghrelin (1-19) 
skeleton was used again for optical imaging of cardiomyocytes by replacing the 
fluorescein dye in the 19th position with a cyanine-5 near-infrared dye. Replacement of 
the dye resulted in a slightly lower binding affinity of 25.8 nM but selective targeting of 
GHS-R1a is still observed. These findings support the use of ghrelin (1-19) as an 
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effective targeting entity in which modifications to position 19 result in minimal effect on 
the overall binding affinity.21  
Development of ghrelin analogues into PET radiopeptides was first demonstrated with a 
therapeutic approach to address obesity, cachexia and anorexia. Ghrelin(1-28) and 
ghrelin(1-16) analogues bearing 1,4,7-triazacyclononane, 1-glutaric acid-4,7-acetic acid 
(NODAGA) for chelation of gallium-68 were studied in vivo and exhibited good receptor 
affinity.22 Ghrelin was also developed as a SPECT radiopeptide by incorporation of 
technetium-99m into the ghrelin sequence using various chelating moieties. These 
analogues also demonstrated good receptor affinity as well as good biological properties 
for further development of ghrelin into diagnostic radiopharmaceuticals.23  
These promising results sparked our interest in developing a ghrelin (1-19) analogue 
capable of bearing a radionuclide in order to detect prostate carcinomas using a more 
sensitive imaging technique. Herein, we describe the synthesis and evaluation of a new 
ghrelin (1-19) analogue capable of chelating gallium-68, a PET radionuclide, and 
describe preclinical in vivo results using this ghrelin-based PET imaging probe. 
2.2 Results and Discussion 
2.2.1 Design and Synthesis 
Structure-activity studies performed on the ghrelin amino acid sequence suggest that only 
the first five N-terminal amino acids are necessary for ghrelin to maintain affinity to 
GHS-R1a. As more N-terminal amino acids are added, for example ghrelin (1-14), the 
binding affinity improves drastically. Recent literature has shown that ghrelin (1-19) is 
able to not only target GHS-R1a, but also tolerate modifications to position 19 without 
having a detrimental effect on binding affinity.20, 21 In order to create a ghrelin-based PET 
imaging probe, the ghrelin (1-19) analogue was modified so as to possess a tris-tert-butyl 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (DOTA) chelator at position 19.   
A non-radioactive Dpr3(octanoyl),Lys19(DOTA)-ghrelin(1-19) analogue (2.3d) was 
synthesized as a reference standard for in vitro assays and radiochemistry. 2.1 was 
truncated to contain the first 19 N-terminal amino acids and synthesized using standard 
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FMOC solid-phase peptide synthesis techniques. In order to increase in vivo stability and 
incorporate a bifunctional chelating moiety, orthogonal protecting groups were used to 
modify residue 3 and 19 (Scheme 2.1). Within natural ghrelin, a unique octanoylated 
chain is appended to the serine side chain by an ester linkage at Ser-3. To reduce the 
occurrence of enzymatic hydrolysis of the ester in vivo, serine was replaced by 
diaminopropionic acid (Dpr). This substitution replaces the labile ester linkage with a 
more robust amide linkage to the octanoylated chain. Structural studies performed by 
Matsumoto et. al. revealed the active core of ghrelin is contained within N-terminal 
region of the peptide,41 therefore the incorporation the bifunctional chelator tris-tert-butyl 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (DOTA) would cause the least 
effect if appended to the C-terminal lysine-19 side chain using a pendant design 
approach. Upon completion of these modifications, 2.3d was purified by preparative 
HPLC. Analytical LC-MS was used to confirm the identity of the products isolated in 
>95% purity. 2.3d was then coordinated to naturally occurring gallium-69/71 using 
gallium(III) nitrate. The non-radioactive reference standard, [69/71Ga]-2.3d, was used in 
further in vitro studies. The identity of the product was also confirmed by analytical LC-
MS and isolated in >95% purity. 
 
Scheme 2.1 Synthesis of 2.3d. 
26 
 
2.2.2 In Vitro Analysis 
To ensure these modifications have had little detrimental effect on receptor binding, a 
competitive binding assay was performed on 2.3d, and [69/71Ga]-2.3d against [125I]-
ghrelin(1-28). The binding affinity was measured in human embryonic kidney-293 cells 
(HEK-293) that were transfected with the GHS-R1a receptor. Varying the concentrations 
of each ghrelin analogue in the presence of [125I] human ghrelin resulted in a sigmoidal 
binding curve in which the half maximal inhibitory concentration (IC50) values can be 
extrapolated (Figure 2.2). As summarized in table 2.1, 2.1 has the 
 
Figure 2.2 Half-maximal inhibitory concentration curves of ghrelin analogues against [125I]-human 
ghrelin in HEK293/GHS-R1a cells. 2.1 (A), 2.3d (B), [69/71Ga]-2.3d (C).   
best binding affinity to GHS-R1a of 2.05 nM. When comparing the ghrelin(1-19) 
analogues, 2.3d and [69/71Ga]-3d, it was observed that [69/71Ga] chelation improves the 
binding affinity from 14.9 nM to 5.1 nM. Matsumoto has explored the effect of charge on 
the C-terminal end of 2.1. They found that elimination of the C-terminal carboxylic acid 
charge by amidation resulted in an eight-fold increase in potency to GHS-R1a.16 This 
same trend is observed upon [69/71Ga] chelation to 3d. The carboxylic functionality 
charges present in the DOTA becomes neutral upon chelation and in turn, results in a 
stronger binding affinity to the GHS-R1a. The synthesized standard, [69/71Ga]-2.3d, 
possesses comparable binding affinity to GHS-R1a as the endogenous ligand 1 as well as 
the potential to be developed into a PET radiopeptide by complexation to radioactive 
gallium-68. 
 
 
log [2.1] (M) log [2.3d] (M) log [69/71Ga-2.3d] (M) 
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Table 2.1 IC50 Values for Synthesized Ghrelin Analogues 2.1, 2.3d and [69/71Ga]-2.3d 
Ghrelin Analogue IC50 (nM) 
2.1 2.05 
2.3d 14.9 
[69/71Ga]-2.3d 5.67 
 
2.2.3 Radiochemistry 
Radiochemistry using gallium-68 (68Ga) has been investigated since the early 1970’s,24 
but it wasn’t until 2001 that breakthrough clinical work published on 68Ga-DOTATOC 
for the imaging of neuroendocrine associated disease resulted in an interest in other 
clinical applications for gallium-68.25 To date, Gallium-68 has been incorporated into 
many peptides, such as bombesin and somatostatin, to visualize various tumour models 
using PET.26 Gallium-68 is a preferred isotope for clinical imaging because it has a short-
lived half life of 68 minutes and decays 89% by positron emission. This isotope is also 
cost-efficient and convenient as it is produced from germanium-68/gallium-68 generators 
and does not require an on-site cyclotron. Gallium-68 is eluted as cationic Ga(III) and is 
often associated with high and reproducible peptide labelling yields.27 
 
Scheme 2.2 Gallium-68 chelation of 2.3d 
Radiolabelling of 2.3d was optimized by varying conditions such as the mass of 
precursor and buffer concentration, in order to maximize radiochemical yield and specific 
activity. In all cases, the reaction mixture was heated at 90°C for 15 minutes before Sep 
Pak reverse-phase purification (Scheme 2.2). The various conditions are highlighted in 
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Table 2.2. Radiolabelling of 50 µg of 2.3d in 1 M HEPES buffer resulted in the best 
decay corrected yield of 96% (d.c) but did not result in a desirable specific activity. In 
order to increase the specific activity, the amount of 2.3d was decreased to 25 µg. These 
conditions maintained respectable yields of 45-91% (d.c) and increased the specific 
activity to more desirable levels, 17.6- 19.0 GBq/µmol. Further reduction of the amount 
of 2.3d to 20 µg resulted in similar yields of 54-83% (d.c) and resulted in the highest 
obtained specific activity of 10.2-22.8 GBq/µmol. A loss of radiochemical yield and 
specific activity was observed when precursor 2.3d was further decreased to 10 µg. 
Overall, the best labelling conditions for 2.3d was determined to be 20 µg of precursor in 
1M HEPES buffer and these radiolabelling conditions remained standard for all 
subsequent studies. The identity of the radiolabelled [68Ga]-2.3d was confirmed by co-
injection with [69/71Ga]-2.3d on RP-HPLC resulting in consistent retention times for the 
radiolabelled and product standard (Figure 2.3). 
Table 2.2 Radiolabelling conditions for [68Ga]-2.3d 
Mass of 
2.3d (µg) 
Buffer Concentration 
(µM) 
Decay Corrected 
Yield (%) 
Specific Activity 
(GBq/µmol) 
100 0.5 M HEPES 7.83 54 4.51 
50 1 M HEPES 3.91 96 3.84-4.28 
25 0.5 M HEPES 1.96 45-91 17.6-19.0 
20 1M HEPES 1.56 54-83 10.2-22.8 
10 1 M HEPES 0.78  17-23 5.39-7.72 
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Figure 2.3 RP-HPLC of [69/71Ga]-2.3d and [68Ga]-2.3d 
2.2.4 In Vitro Evaluation of 68Ga-Ghrelin (1-19) 
The uptake of [68Ga]-2.3d was evaluated in GHS-R1a transfected HEK293 cells. After 60 
minutes of incubation of [68Ga]-2.3d with the GHS-R1a expressing cells, each of the cell 
pellets (n=6) were placed on a gamma counter and quantified into counts per minute 
(cpm). To ensure [68Ga]-2.3d is specifically targeting the same binding site on GHS-R1a, 
a blocking study was performed by administering non-radioactive 2.1 prior to [68Ga]-
2.3d. 2.1 is expected to bind the majority of available GHS-R1a before administration of 
[68Ga]-2.3d and result in a decreased cpm as [68Ga]-2.3d is no longer able to associate to 
these receptors. As seen in Figure 2.4, HEK293/GHS-R1a cells averaged 24744 
counts/second in the presence of [68Ga]-2.3d. When 2.1 is introduced along with the 
68Ga-ghrelin, the activity taken up by the cells drops by 54%. This evidence supports that 
2.1 and [68Ga]-2.3d occupy the same binding region on the GHS-R1a. 
  
Figure 2.4 Uptake of [68Ga]-2.3d in HEK293/GHS-R1a cell with and without blocking of GHS-R1a with 
2.1. 
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2.2.5 In Vivo Evaluation of 68Ga-Ghrelin (1-19) 
To evaluate the effectiveness of the ghrelin-based PET imaging probe, an in vivo 
preclinical study was performed with two cell lines, HT1080/GHS-R1a and HT1080. 
These chosen cells lines will demonstrate the uptake of the radioligand in a xenograft 
overexpressing the receptor of interest compared to a xenograft with normal expression. 
[68Ga]-2.3d was studied in vivo in NOD/SCID male mice bearing a HT1080/GHS-R1a 
xenograft tumour. As a negative control model, mice bearing HT1080 xenografts were 
also studied.  Each mouse was administered 7-10 MBq of [68Ga]-2.3d in a saline solution 
and immediately underwent a 60 minute µPET dynamic scan. The dynamic scans were 
processed into 10 minute intervals to monitor the uptake and accumulation of [68Ga]-2.3d 
in the tumour and other organs and tissues. A coronal µPET image (Figure 2.5A) and a 
three-dimensional projection (Figure 2.5C) from the small animal PET scanner was taken 
at the 30 to 40 minute time interval in the negative control HT1080 mice. The most 
notable uptake is visualized in the kidneys (k) and bladder (b). The tumour (t) is present 
on the right flank and accumulated a small amount of residual radioactivity. The residual 
radioactivity can be attributed to circulation of the [68Ga]-2.3d and its metabolites 
through the highly vascularized tumour rather than association to receptors in the 
HT1080 cell line. A coronal µPET image (Figure 2.5B) and a three-dimensional 
projection (Figure 2.5D) from the small animal µPET scanner was also taken at the 30 to 
40 minute time interval in the positive HT1080/GHS-R1a mice. Similar to the control, 
there is high uptake in the kidneys (k) and the bladder (b). More radioactivity has now 
been localized and retained in the tumour (t) on the left flank. The retention of the probe 
is believed to be due to the active binding of [68Ga]-2.3d to GHS-R1a in the xenograft. 
The high localization of radioactivity to the kidneys is a common trait seen in 
radiolabelled peptides as through tubular reabsorption. Radiolabelled peptides often 
become trapped causing undesirable effects such as nephrotoxicity and this can be 
combated by reducing the presence of charged side chains within the peptide or 
administering a cationic amino acid prior to injection of the radiolabelled peptide.28  
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Figure 2.5 A 60 minute dynamic uPET scan showing uptake of [68Ga]-2.3d from 30-40 minutes in 
HT1080 and HT1080/GHS-R1a xenografts. (A) HT1080 – coronal. (B) HT1080/GHS-R1a – coronal, (C) 
HT1080 – 3D projection and (D) HT1080/GHS-R1a – 3D projection. 
To more accurately compare the uptake of [68Ga]-2.3d in both tumour models, standard 
uptake values (SUV) were calculated by designating volumes of interest (VOI) for each 
xenografts over the 60 minute scan using AsiPro software. The SUVs were calculated 
using Equation 2.1 (supplemental materials) and graphed in Figure 2.6. The SUV for 
HT1080/GHS-R1a xenograft mice is approximately 5 times greater than the HT1080 
xenografts. These results show [68Ga]-2.3d is selective to xenografts that contain GHS-
R1a receptors compared to those with limited receptor expression, such as the control 
HT1080 cell line.  
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Figure 2.6 Graphical representation of SUVs for [68Ga]-2.3d in HT1080/GHS-R1a and HT1080 
xenographs over 60 minutes. 
2.2.6 Conclusions 
The objective of this work was to develop a ghrelin-based PET imaging probe capable of 
targeting the endogenous GHS-R1a with comparable affinities to the natural ligand. 
Truncating ghrelin (1) to the first 19 N-terminal amino acids and modifying positions 3 
and 19 not only increased the stability and introduced a bifunctional chelator, these 
modifications provided a high affinity ligand to GHS-R1a. IC50 studies determined that 
the 69/71Ga-ghrelin complex had an improved IC50 value compared to the non-coordinated 
2.3d. When evaluated in vivo, [68Ga]-2.3d shows localization in HT1080/GHS-R1a 
xenografts within the first 30 minutes of circulation that is not present in the HT1080 
negative control. Examining the SUV values over 60 minutes in each xenograft results in 
approximately 5 times greater uptake [68Ga]-2.3d in the presence of GHS-R1a. The high 
localization of [68Ga]-2.3d in the kidneys raises a concern for nephrotoxicity and suggests 
the need for further optimization of this analogue. Smaller ghrelin analogues are currently 
being developed in hopes of decreasing kidney retention and optimizing pharmacokinetic 
behaviour. 
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2.3 Experimental 
2.3.1 Materials and Methods 
All common solvents were purchased from Fisher Scientific. All protected amino acids, 
coupling reagents and resins were purchased from Novabiochem, Peptides International 
and Chem-Impex and were used without further purification unless otherwise stated. All 
reagents were obtained from Sigma-Aldrich with the exception of gallium (III) nitrate 
hydrate that was obtained from Strem Chemicals, HEPES free acid that was obtained 
from AMRESCO and tris-t-butyl DOTA that was obtained from CheMatech. RP-tC18 
Sep-Pak SPE cartridges were purchased from Waters. [125I]-ghrelin was purchased from 
Perkin Elmer. The germanium/gallium generator and all its corresponding parts were 
purchased from Eckert and Ziegler Strahlen- und Medizintechnik AG. For analytical 
HPLC-MS, a Sunfire RP-C18 4.6 x 250 mm, 5 µm column was used. For preparative 
HPLC-MS work, a Sunfire RP-C18 19 x 150 mm, 5 µm column was used. A gradient 
solvent system was used containing 0.1% TFA in acetonitrile (solvent A) and 0.1% TFA 
in water (solvent B). For analytical UHPLC-MS, studies were performed on a Waters, 
Inc. Acquity UHPLC H-Class system, combined with a Xevo QTof mass spectrometer 
(ESI+, cone voltage = 30 V). For analytical UHPLC-MS studies, a Waters Acquity 
UHPLC BEH C18 2.1 x 50 mm, 1.7 µm column was used with a gradient solvent system 
consisting of 0.1% formic acid in acetonitrile (solvent C) and 0.1% formic acid in water 
(solvent D). Analytical radio-RP-HPLC (SunfireTM RP-C18 column 4.6 x 150 mm, 5 µm) 
was performed on a Waters 1525 Binary HPLC pump containing a Waters 2487 dual λ 
absorbance detector, Waters in-line degasser, a gamma detector and Breeze software 
(version 3.30). 
2.3.2 Synthesis of 2.3d 
Peptide synthesis was carried out manually using FMOC-based solid-phase peptide 
chemistry. Peptides were synthesized at a 0.1 mmol scale on Rink Amide MBHA resin 
(0.51 mmol/g). The resin was initially swelled with N,N-dimethylformamide (DMF), 
followed by FMOC deprotection using 2 mL of 20% piperidine in N,N-
dimethylformamide (DMF) for two cycles (10 minutes, 5 minutes). Amino acids were 
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preactivated by combining 3 eq. of Fmoc-protected amino acid, 3 eq. of HCTU and 6 eq. 
of N,N-diisopropylethylamine (DIPEA) in 2 mL of DMF. The mixture was added to the 
resin and coupled for 30 minutes and repeated again for 60 minutes. These cycles were 
repeated until all 19 N-terminal amino acids were coupled to the resin. 
Methyl trityl deprotection was carried out by mixing the resin with 2 mL of 2% 
trifluoroacetic acid (TFA) + 5% triisopropylsilane (TIS) in dichloromethane (DCM) 
solution for 2 minutes and repeating for 8 cycles, or until the yellow colour no longer 
persisted. To neutralize residual TFA, the resin was treated with 200 µL of DIPEA in 
DMF for 5 minutes. Octanoic acid was coupled to the resulting free amine using 3 eq. 
octanoic acid, 3 eq. HCTU and 3 eq. of DIPEA in DMF. The mixture was left to couple 
overnight.  
Allyloxycarbonyl deprotection was performed under inert atmospheric N2 conditions. 
DCM was dried over sieves for 24 hours before adding 1 mL to the resin. 2 eq. of 
phenylsilane in 1 mL dry DCM was then added to the peptide resin followed by 0.045 eq. 
of tetrakis(triphenylphosphine) palladium (0) in 1 mL dry DCM. The peptide vessel was 
removed from inert conditions and allowed to react for 30 minutes. The resulting free 
amine was coupled to the chelator using 2 eq. of tris-t-butyl DOTA, 2 eq. of HCTU and 6 
eq. of DIPEA in DMF. The reaction mixture was left to couple overnight.  
Full deprotection of the synthesized peptide was performed by adding a 2 mL mixture of 
95% TFA, 2.5% TIS and 2.5% water to the resin and allowed it to mix for 5 hours. The 
cleaved peptide was precipitated from solution using ice-cold tert-butyl methyl ether 
(TBME) and centrifuged (3000 rpm, 10 minutes) resulting in a crude peptide pellet. The 
supernatant was decanted and the resulting peptide pellet was dissolved in 20% 
acetonitrile in water, frozen at -78 °C and lyophilized to a white crude powder. 
Purification was performed using preparative HPLC-MS on a gradient of 20% to 60% 
solvent A in B over 10 minutes. Purity of the resulting peptide was analyzed using 
analytical UHPLC on a gradient of 10% to 60% solvent C in D over 4 minutes. Pure 
peptide was isolate in a 21% yield. HRMS (ESI+): m/z calculated for C118H195N38O37, 
[M+2H]2+ = 1370.2927, observed [M+2H]2+= 1370.1941 
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2.3.3 Synthesis of [69/71Ga]-2.3d 
Purified 2.3d (5 mg) was dissolved in 1 mL of distilled water in a 5 mL pear-shaped 
round bottom flask. Ga(NO3)3 (20 eq., 8 mg) was added to the flask and stirred at 60 °C 
for one hour. The reaction mixture was diluted with 3 mL of distilled water and loaded 
onto a tC18 Sep Pak SPE cartridge. The cartridge was rinsed with 2 mL of distilled water 
to remove excess gallium, and [69/71Ga]-2.3d was eluted from the cartridge with 3 mL of 
50% ACN/H2O (3 x 1 mL aliquots). Each aliquot was analyzed by RP-UHPLC to 
confirm the identity and purity of [69/71Ga]-2.3d. Pure [69/71Ga]-2.3d was isolated in 86% 
yield. HRMS (ESI+): m/z calculated for C118H193N38O3769Ga, [M+2H]2+ = 1403.6979, 
observed [M+2H]2+= 1403.8301. 
2.3.4 Radiochemistry 
A sterile 10 mL reaction vial was loaded with 2.3d (10 – 100 µg) in HEPES buffer (0.5 – 
1 M, pH 4); all conditions can be found in Table 1. Fresh radioactive 68Ga3+ was eluted 
from a 68Ge/68Ga generator using 0.1 M hydrochloric acid (HCl) and trapped on a Strata 
X C cation exchange column. The column was eluted with 0.1 M HCl in acetone to 
transfer 68Ga3+ to the reaction vial. In all cases, the solution was heated to 90 oC for 15 
minutes followed by dilution with 3 mL of milliQ water. The diluted mixture was loaded 
onto a precondition tC18 sep pak SPE cartridge to remove unchelated 68Ga3+. The 
radiolabelled peptide was eluted with 1 mL of ethanol into a sterile product vial. Specific 
activities were calculated by assuming all unlabelled 2.3d remains present in the product 
vial. The optimal manual labelling conditions were obtained with 20 µg of 2.3d in 1 M 
HEPES buffer. The radiolabelled peptide was obtained in a 54-83% decay corrected yield 
and specific activity of 10.2 – 22.8 GBq/µmol. Radiochemical purity was assessed using 
RP-HPLC coupled to a gamma detector, prior to use in in vitro and in vivo assays. 
2.3.5 Competitive Binding Assays (IC50) 
The affinity for GHS-R1a was determined using a radioligand binding assay. Assays 
were performed using GHS-R1a transfected HEK293 cells as receptor source and human 
[125I]-ghrelin(1-28)  (PerkinElmer Inc.) as radioligand. Human ghrelin(1-28) was used as 
reference to ensure the validity of the results. [69/71Ga]-3d and 3d (at concentrations of 10-
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5 M, 10-6 M, 10-7 M, 10-8 M, 10-9 M, 10-10 M and 10-11 M) and [125I]-ghrelin (15 pM per 
assay tube) were mixed in binding buffer (25 mM HEPES, 5 mM magnesium chloride, 1 
mM calcium chloride, 2.5 mM EDTA, and 0.4% BSA, pH 7.4). A suspension of 
membrane from HEK293S cells (50,000 cells per assay tube) was added to the assay tube 
containing test peptides and [125I]-ghrelin(1-28). The resulting suspension was incubated 
for 20 minutes under shaking (550 rpm). Unbound [125I]-ghrelin was removed and the 
amount of [125I]-ghrelin bound to the membranes was measured on a gamma counter. 
IC50 values were determined by nonlinear regression analysis to fit a 4 parameter dose 
response curve using GraphPad Prism (Version 6.0c) and summarized in Table 2.2. All 
binding assays were performed in triplicate.29 
2.3.6 In Vitro Evaluation of [68Ga]-2.3d 
[68Ga]-2.3d was incubated with 1 million HEK293/GHS-R1a cells (n=6) in 1 mL of 
binding buffer (25 mM HEPES, 5 mM MgCl2, 1 mM CaCl2, 2.5 mM EDTA, 0.4% BSA)  
for 1 hour at 37 oC. After 1 hour, the cells were pelleted, washed thoroughly with binding 
buffer (3 x 1 mL) and the radioactivity was measured using a gamma counter. Blocking 
studies were performed by administering 20 equivalents (20 µg) of human ghrelin to 1 
million HEK293/GHS-R1a cells (n=6) in 1 mL of binding buffer and immediately before 
administering [68Ga]-2.3d. The mixture was incubated for 1 hour at 37oC, pelleted, 
washed and the radioactivity measured using a gamma counter. Measurements were 
recorded in counts/second and used to calculate the mean and standard deviation. 
2.3.7 In Vivo Evaluation 
In vivo imaging studies were carried out in two cell lines, HT1080/GHS-R1a (receptor 
positive) and HT1080 (natural expression). HT1080 xenografts were grown on the right 
upper flank of male NOD/SCID mice by injecting two million cells of HT1080 (n=1) 
while HT1080/GHS-R1a xenografts were grown on the left flank by injecting two million 
cells of HT1080/GHS-R1a (n=1). Tumours of approximately 1 centimeter in diameter, 
were present two weeks post injection. Each mouse was administered 7-10 MBq of 
[68Ga]-2.3d via tail vein injection. A 60-minute dynamic small animal PET scan was 
performed on both cell lines (Figure 5A-D). 
37 
 
µPET scans were reconstructed using CarimasTM software developed at the Turku PET 
Centre (Turku, Finland).30 To reduce variability due to mouse size and injected dose, all 
radiotracer accumulation was quantified with respect to standard uptake values (SUV) 
and normalized to the kidney uptake, therefore µPET scans are represented as SUV ratio 
(SUVr) values. SUVs were determined using AsiPro software (Concorde Microsystems, 
Knoxville, Tenn, USA). Volumes of interest (VOI) were contoured by hand resulting in 
3D reconstruction of the tumour. The image derived radioactivity concentration (Bq/cc) 
was determined for each VOI based on the injected dose. Standard uptake values (SUV) 
are then calculated using equation 2.1 (supplemental materials) where SUV(t) is the 
standard uptake value at time t, C(t) is the imaged derived radioactivity concentration in 
Bq/cc, ID(t) is the injected dose at time t, and W is the weight of the mouse in grams. 
2.4 Acknowledgements 
HEK293/GHS-R1a cells were provided by Dr. Savita Dhanvantari of Lawson Health 
Research Institute and HT1080/GHS-R1a cells were provided by Dr. Hon Leong of the 
London Region Cancer Program. Funding from the Canadian Institutes for Health 
Research (CIHR), Prostate Cancer Canada and the London Regional Cancer Program.  
2.5 References 
1. M. Kojima, H. Hosoda, Y. Date, M. Nakazato, H. Matsuo and K. Kangawa, 
Nature, 1999, 402, 656-660. 
2. P. L. Jeffery, A. C. Herington and L. K. Chopin, Cytokine Growth Factor Rev, 
2003, 14, 113-122. 
3. A. Pedretti, M. Villa, M. Pallavicini, E. Valoti and G. Vistoli, J. Med. Chem., 
2006, 49, 3077-3085. 
4. S. Gnanapavan, B. Kola, S. A. Bustin, D. G. Morris, P. McGee, P. Fairclough, S. 
Bhattacharya, R. Carpenter, A. B. Grossman and M. Korbonits, J Clin Endocrinol 
Metab, 2002, 87, 2988. 
38 
 
5. L. Chopin, C. Walpole, I. Seim, P. Cunningham, R. Murray, E. Whiteside, P. Josh 
and A. Herington, Mol Cell Endocrinol, 2011, 340, 65-69. 
6. A. H. Yeh, P. L. Jeffery, R. P. Duncan, A. C. Herington and L. K. Chopin, Clin 
Cancer Res, 2005, 11, 8295-8303. 
7. P. Cassoni, E. Allia, T. Marrocco, C. Ghe, E. Ghigo, G. Muccioli and M. Papotti, 
J Endocrinol Invest, 2006, 29, 781-790. 
8. F. Gaytan, C. Morales, M. L. Barreiro, P. Jeffery, L. K. Chopin, A. C. Herington, 
F. F. Casanueva, E. Aguilar, C. Dieguez and M. Tena-Sempere, J Clin Endocrinol 
Metab, 2005, 90, 1798-1804. 
9. F. Gaytan, M. L. Barreiro, J. E. Caminos, L. K. Chopin, A. C. Herington, C. 
Morales, L. Pinilla, R. Paniagua, M. Nistal, F. F. Casanueva, E. Aguilar, C. 
Dieguez and M. Tena-Sempere, J Clin Endocrinol Metab, 2004, 89, 400-409. 
10. R. Wasko, M. Jaskula, M. Kotwicka, M. Andrusiewicz, A. Jankowska, W. Liebert 
and J. Sowinski, Neuro Endocrinol Lett, 2008, 29, 929-938. 
11. N. Diaz-Lezama, M. Hernandez-Elvira, A. Sandoval, A. Monroy, R. Felix and E. 
Monjaraz, Biochem Biophys Res Commun, 2010, 403, 24-29. 
12. J. N. Fung, I. Seim, D. Wang, A. Obermair, L. K. Chopin and C. Chen, Horm 
Cancer, 2010, 1, 245-255. 
13. M. S. Duxbury, T. Waseem, H. Ito, M. K. Robinson, M. J. Zinner, S. W. Ashley 
and E. E. Whang, Biochem. Biophys. Res. Commun., 2003, 309, 464-468. 
14. T. Waseem, R. Javaid Ur, F. Ahmad, M. Azam and M. A. Qureshi, Peptides, 
2008, 29, 1369-1376. 
15. D. Rosita, M. A. DeWit and L. G. Luyt, J Med Chem, 2009, 52, 2196-2203. 
39 
 
16. M. Matsumoto, H. Hosoda, Y. Kitajima, N. Morozumi, Y. Minamitake, S. 
Tanaka, H. Matsuo, M. Kojima, Y. Hayashi and K. Kangawa, Biochem. Biophys. 
Res. Commun., 2001, 287, 142-146. 
17. M. A. Bednarek, S. D. Feighner, S.-S. Pong, K. K. McKee, D. L. Hreniuk, M. V. 
Silva, V. A. Warren, A. D. Howard, L. H. Y. Van der Ploeg and J. V. Heck, J 
Med Chem, 2000, 43, 4370-4376. 
18. M. Van Craenenbroeck, F. Gregoire, P. De Neef, P. Robberecht and J. Perret, 
Peptides, 2004, 25, 959-965. 
19. R. McGirr, M. S. McFarland, J. McTavish, L. G. Luyt and S. Dhanvantari, Regul. 
Peptides, 2011, 172, 69-76. 
20. C. Lu, M. S. McFarland, R.-L. Nesbitt, A. K. Williams, S. Chan, J. Gomez-
Lemus, A. M. Autran-Gomez, A. Al-Zahrani, J. L. Chin, J. I. Izawa, L. G. Luyt 
and J. D. Lewis, The Prostate, 2012, 72, 825-833. 
21. G. A. F. Douglas, R. McGirr, C. L. Charlton, D. B. Kagan, L. M. Hoffman, L. G. 
Luyt and S. Dhanvantari, Peptides, 2014, 54, 81-88. 
22. C. Chollet, R. Bergmann, J. Pietzsch and A. G. Beck-Sickinger, Bioconjug Chem, 
2012, 23, 771-784. 
23. P. Koźmiński and E. Gniazdowska, Nucl. Med. Biol., 2015, 42, 28-37. 
24. M. A. Green and M. J. Welch, Int J Rad Appl Instrum B, 1989, 16, 435-448. 
25. M. Henze, J. Schuhmacher, P. Hipp, J. Kowalski, D. W. Becker, J. Doll, H. R. 
Macke, M. Hofmann, J. Debus and U. Haberkorn, J. Nucl. Med., 2001, 42, 1053-
1056. 
26. H. R. Maecke, M. Hofmann and U. Haberkorn, J Nucl Med, 2005, 46 Suppl 1, 
172S-178S. 
27. S. R. Banerjee and M. G. Pomper, Appl Radiat Isot, 2013, 76, 2-13. 
40 
 
28. A. Choudhary and R. T. Raines, Chem Biochem, 2011, 12, 1801-1807. 
29. B. Behnam Azad, V. A. Rota, D. Breadner, S. Dhanvantari and L. G. Luyt, 
Bioorg. Med. Chem., 2010, 18, 1265-1272. 
30. S. V. Nesterov, C. Han, M. Maki, S. Kajander, A. G. Naum, H. Helenius, I. 
Lisinen, H. Ukkonen, M. Pietila, E. Joutsiniemi and J. Knuuti, Eur J Nucl Med 
Mol Imaging, 2009, 36, 1594-1602. 
 
  
41 
 
Chapter 3 
3 Structural-Activity Study of Ghrelin(1-8) Resulting in 
Potent Fluorine-bearing Ligands for GHS-R1a 
3.1 Introduction 
The recent advances in the field of molecular imaging have vastly influenced disease 
monitoring, staging and diagnosis. Molecular imaging techniques, such as optical 
imaging (OI), positron emission tomography (PET) and single-photon emission 
computed tomography (SPECT), have been used to develop a better understanding of 
specific molecular events occurring within a disease state.1 The field of oncology has 
greatly benefitted from developments in molecular imaging. Classical methods of cancer 
diagnosis, such as histology, are slowly being replaced by new non-invasive methods 
developed through molecular imaging. One approach to developing these methodologies 
is identifying molecular receptors involved in the proliferation, migration and cell 
invasion processes associated with cancer progression and using them as a marker for the 
disease.2 For example, somatostatin receptors are highly expressed on the cell surface of 
specific neoplastic tissues. Considerable research effort has been dedicated to targeting 
this receptor using its endogenous peptide ligand, somatostatin. Unfortunately, the 
naturally occurring 28-mer and 14-mer somatostatin ligands are known to have poor in 
vivo stability. In an effort to improve metabolic stability, collections of modified 
somatostatin analogues were developed by structure-activity studies. From these 
analogues, a cyclic octapeptide, known as octreotide, was found to be more stable than 
somatostatin. Using a pendant design approach, chelating moieties were appended to the 
cyclic peptide to incorporate various radiometals such as 64Cu, 68Ga and 111In. These 
analogues are now capable of detecting neuroendocrine tumours using scintigraphy and 
have been evaluated in preclinical and clinical studies.3-5 This approach to designing 
stable, high affinity peptide ligands for tumour receptors has led to many new peptide 
ligands based off of integrin, gastrin-releasing peptide, cholestokinin and alpha-
melanocyte stimulating hormone and continues to be an area of focus for designing new 
receptor-binding peptide ligands. 
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 An exciting new receptor holding potential relevance to certain cancers is the 
growth-hormone secretagogue receptor (GHS-R). GHS-R has been detected in two 
isoforms. GHS-R1a is a G-protein coupled receptor known to induce growth-hormone 
release, as well as various other functions, mediated by its endogenous ligand ghrelin. 
GHS-R1b is a truncated 5-transmembrane receptor found to be functionally inactive and 
possessing no known endogenous ligands.6 Initially, it was proposed that GHS-R1a was 
solely expressed in the pituitary and hypothalamus but more intensive studies show that 
although GHS-R1a is predominately expressed in the pituitary, it is also present in low 
levels in peripheral tissues including the thyroid, pancreas, spleen, myocardium and 
adrenal gland.6 More importantly, GHS-R1a is differentially expressed in healthy human 
tissues and several tumour types such as prostate, breast, testicular and ovarian 
carcinomas.7-11  
 
Figure 3.1 Preproghrelin undergoes proteolytic cleavage resulting in desacyl ghrelin (3.1) which 
undergoes acylation by ghrelin O-acyl transferase resulting in ghrelin(1-28) (3.2). 
 The endogenous ligand for GHS-R1a is ghrelin (3.2), a 28 amino acid peptide 
hormone (GSS(octanoyl)FLSPEHQRVQQRKESKKPPAKLQPR) that possesses a 
unique octanoyl chain on the serine side chain at position 3. Human ghrelin originates 
from preproghrelin, a 177-amino acid protein that undergoes proteolytic cleavage to a 28 
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amino acid peptide known as desacyl ghrelin (3.1). Compound 3.1 possesses the same 
amino acid sequence as 3.2, but lacks the octanoyl chain present at position 3.12 Without 
the octanoyl chain, 3.1 has virtually no affinity (IC50 > 10000 nM) affinity to GHS-R1a 
as determined by a competitive binding assay. 3.1 then undergoes acylation by the 
ghrelin O-acyl transferase (GOAT) to yield the unique octanoyl modification. It is this 
unique modification that significantly increases the affinity to GHS-R1a to 2.05 nM 
(Figure 3.1).13  
Ghrelin provides a high affinity template as a starting point to further develop into a 
radiopeptide. Like many other peptides, ghrelin lacks in vivo stability and requires 
modifications such as truncation and amino acid substitution in order to resist in vivo 
degradation and maintain affinity to GHS-R1a. Much like somatostatin, a methodical 
structural activity study of ghrelin will help to better understand the role each amino acid 
plays in the interaction with GHS-R1a. We propose that truncation of ghrelin to the first 
eight N-terminal amino acids will result in high affinity ghrelin analogues by selectively 
modifying amino acids important for receptor interaction. We will also incorporate a 
radionuclide into the ghrelin scaffold that is integral for receptor interaction. This 
requires the development of a new fluorine-18 prosthetic group and results in a high 
affinity ghrelin(1-8) analogue capable of targeting GHS-R1a. 
3.2 Results and Discussion 
3.2.1 Design of Ghrelin Analogues for Positron Emission 
Tomography (PET) 
A significant quantity of literature has focused on describing studies where the ghrelin(1-
28) structure is modified in order to determine the portions necessary for activity, the role 
of the octanoyl chain, as well as determining the shortest peptide fragment to activate the 
receptor.14, 15 Matsumoto et al. determined that the C-terminal region of the peptide, 
ghrelin(16-28), has no affinity to the GHS-R1a. The N-terminal region of the peptide was 
then investigated to determine how many amino acids must be maintained to ensure 
affinity to GHS-R1a. When truncated to the first 14 N-terminal amino acids, ghrelin(1-
14), affinity to GHS-R1a remained respectable with an IC50 of 9.6 nM. As further 
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truncation occurred, there was an increasing loss of affinity for the receptor. For example, 
ghrelin(1-10) has an IC50 of 19 nM while ghrelin(1-4) has an IC50 of 480 nM.  When 
ghrelin was truncated to less than 4 amino acids, all affinity to the receptor was lost 
suggesting the first 4 amino acids play an integral role in the affinity to GHS-R1a.14  
When VanCraenenbroeck et al. studied ghrelin(1-14) analogues, they discovered that 
placing an alanine or tyrosine in position 8 resulted in the most potent ghrelin(1-14) 
analogues. These findings suggest that the negatively charged glutamic acid found in 
natural ghrelin is not the optimal choice for this position.  Synthesizing several ghrelin(1-
8) analogues that replace glutamic acid with various hydrophobic or polar-uncharged side 
chains could result in an optimal amino acid capable of targeting GHS-R1a with equal or 
greater affinity then ghrelin(1-28).16 Modifications were made to positions 3 and 8 while 
the other amino acids remained the same as the natural ghrelin sequence. At position 3, 
serine was replaced with the unnatural amino acid diaminopropionic acid (Dpr) to replace 
the ester linkage with a more synthetically facile and stable amide linkage.17, 18 Octanoic 
acid was added to the side chain of Dpr using standard coupling conditions. Position 8 
was modified to contain all the hydrophobic aromatic side chain amino acids; 
phenylalanine (F), tyrosine (Y) and tryptophan (W), and compared to the natural 
sequence bearing glutamic acid (E). The binding affinity to GHS-R1a was determined 
using a previously reported competitive binding assay.18 As summarized in Table 3.1, E 
as residue 8 resulted in an IC50 of 200 nM but replacing this residue with hydrophobic 
aromatic side chain greatly increased the binding affinity. W and Y were less effective 
substitutions resulting in 86.3 nM (3.3c) and 65.0 nM (3.3a), respectively, while the 
binding affinity substantially increased with F to 6.67 nM (3.3b). Position 8 was also 
substituted with amino acids bearing polar-uncharged side chains; serine (S), asparagine 
(N), glutamine (Q) and threonine (T). These substitutions lead to higher affinity 
analogues than the hydrophobic aromatic side chains. The best analogue 3.3f (Figure 
3.2A), with T in the 8th position, had a 3.26 nM IC50, while N (3.3d), S (3.3g) and Q 
(3.3e) were less effective with 31.9 nM, 28.8 nM and 21.7 nM respectively.  
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Table 3.1 : Substitution of residue 8 with various natural and unnatural amino acids and the resulting 
IC50 (nM) for GHS-R1a. 
 
 
 
Figure 3.2 IC50 curves of lead analogues 3.3f (A), 3.5b (B) and 3.6a (C) after modifications were made 
to positions 8, 1 and 4, respectively. 
One drawback to using peptides as targeting entities is the in vivo stability of peptides. 
For example, natural human ghrelin(1-28) has a biological half-life on the scale of 9-12 
minutes.19 In order to increase the stability of the developed ghrelin(1-8) analogues, 
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bioisosteres can be added to reduce degradation by endopeptidases and exopeptidases. 
Bioisosteres are chemical groups that possess similar physical and chemical properties to 
another chemical compound as well as elicit similar biological properties.20 Bioisosteres 
of F and T, the two lead modifications to position 8, were incorporated into the peptide 
sequence in hopes of maintaining the affinity to GHS-R1a of the natural amino acid as 
well as increasing the overall stability of the peptide. As summarized in Table 3.1, two 
bioisosteres of T were introduced, D-threonine (3.3h) and β-homo-threonine (3.3i). These 
modifications had a negative effect on binding affinity by increasing the IC50 to 66.0 nM 
and 45.0 nM, respectively. 2-Naphthylalanine (2-Nal, 3.3j) was also introduced as a non-
classical bioisostere for F and also had a negative effect on IC50, increasing it 24.8 nM. 
Overall, two amino acids were found to more effectively increase binding affinity than E. 
These two amino acids are F (3.3b) and T (3.3f). 
Bednarek, et al. investigated the importance of the octanoyl chain by evaluating several 
analogues where serine-3 was acylated with different aliphatic and aromatic acids. When 
serine-3 is acylated with large aliphatic groups, such as 11-undecanoic acid, the affinity 
to GHS-R1a is as effective as natural human ghrelin. Yet, when small, less hydrophobic 
acids are present, such as formic acid, all affinity to GHS-R1a is lost. This investigation 
demonstrates that ghrelin is able to tolerate large lipophilic groups at position 3 and 
possibly provides the opportunity to create a short ghrelin analogue with a radioisotope 
integrated into the side chain at position 3.13 To test this hypothesis, Rosita et. al. 
integrated lipophilic groups bearing fluorine-19 and rhenium-185/187 in position 3 of 
ghrelin(1-14)-amide to investigate the potential as PET imaging agents for GHS-R1a. 
The most promising fluorine-19 group contained a 12-carbon chain, the IC50 was 27.9 nM 
and the most promising rhenium-185/187 contained a cyclopentadienyl-rhenium complex 
after a 3-carbon chain that resulted in a 35 nM affinity. These analogues were not further 
developed into PET imaging agents but acted as inspiration for further development of 
ghrelin(1-8) analogues that require a radioisotope for association to the native receptor.21  
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Table 3.2 Substitution of Dpr side chain with various fluorine-bearing aromatic prosthetic groups and the 
resulting IC50 (nM) for GHS-R1a. 
 
Since it was demonstrated that large lipophilic groups were tolerated in position 3, we 
chose to integrate a well-known fluorine-18 prosthetic group, 4-fluorobenzoic acid (4-
FBA), at the end of the Dpr side chain. 4-[18F]FBA has been used to radiolabel various 
peptides such as RGD and bombesin, and has well developed radiochemical 
procedures.22, 23 Shown in Table 3.2, integration of 4-FBA (3.4a) onto residue 3 resulted 
in a less than optimal IC50, of 65 nM. In order to increase the lipophilicity of the 
prosthetic group, another aromatic ring was added by introducing 6-fluoronaphthoic acid 
(6-FNA, 3.4b) and 4’-fluoro-[1,1’-biphenyl]-4-carboxylic acid (4’-FBC, 3.4c) using 
standard coupling conditions. The increased lipophilicity had a positive effect on binding 
affinity to 9.9 nM and 3.5 nM, respectively, and led us to develop a new fluorine-18 
prosthetic group. Unfortunately nucleophilic aromatic substitution with the biphenyl 
scaffold proved to be low yielding and therefore, 6-FNA was further developed into a 
prosthetic group rather than 4’-FBC. 
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Table 3.3 Substitution of residue 1 and 4 with various unnatural amino acids and the resulting IC50 (nM) 
for GHS-R1a. 
 
Following the choice of a suitable prosthetic group for position 3, further modifications 
were made to the N-terminal residue 1 and residue 4 in hopes of further increasing in vivo 
stability and GHS-R1a affinity using more unnatural amino acids. The N-terminal glycine 
was replaced with one of three unnatural amino acids; aminoisobutyric acid (Aib), 
isonipecotic acid (Inp) or sarcosine (Sar). The secondary amine found in Sar (3.5c) had a 
large negative effect on IC50 causing it to rise to 262 nM, while the secondary amine 
found in Inp (3.5b, Figure 3.2B) had the opposite effect decreasing it to a desirable IC50 
of 9.64 nM. Aib, a primary amine, also had a positive effect on IC50 decreasing it to 9.26 
nM (Table 3.3).  When choosing the most suitable candidate for residue 1, Inp was 
chosen in order to reduce the presence of primary amines during the radiochemical 
prosthetic group labelling. VanCraenenbroeck performed an alanine scan on ghrelin(1-
14) and determined that the Phe present at residue 4 was integral for interaction with 
GHS-R1a. Replacement of this residue with alanine or tyrosine caused a decrease in 
binding affinity.16 Therefore, we hypothesized that replacing Phe with a larger, more 
lipophilic side chain may create a stronger interaction between the ligand and receptor. 
Substitution of Phe with Nal-1 and Nal-2 had varied success (Table 3.3). Nal-1 was able 
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to increase the affinity to GHS-R1a greatly from 65 nM (3.4a) to 4.12 nM (3.6a, Figure 
3.2C) while Nal-2 had a detrimental effect result in a large loss of affinity.  
A thorough investigation into the amino acid sequence of ghrelin(1-8)-amide has led to 
many analogues with binding affinities comparable to ghrelin(1-28). Combining the most 
successful substitutions has led to a lead peptide analogue (Figure 3.3) to be further 
developed into a fluorine-18 PET imaging agent. The best substitutions were Inp, Nal-1 
and Thr in positions 1, 4 and 8, respectively and coupling 4-FNA to the side chain of Dpr 
at position 3. Compound 3.7 resulted in the best IC50 of all ghrelin analogues at 0.16 nM 
and supported the further development of this peptide into a PET radiopeptide by 
incorporating fluorine-18. 
 
Figure 3.3 Amino acid structure (A) and IC50 curve (B) of the the ghrelin (1-8) analogue bearing lead 
modifications to all positions 1, 3, 4 and 8. 
 
3.2.2 Synthesis of Prosthetic Groups and Standards 
The synthesis of the new prosthetic group precursor 3.11 is outlined in scheme 3.1. 
Prosthetic group precursor 3.11 was obtained in good yield following a 3-step synthesis. 
The commercially available starting material, 6-amino-2-naphthoic acid (3.8), was 
dissolved in ethanol and acidified with sulfuric acid (pH 4) to produce 6-amino-2-ethyl 
naphthoate (3.9). Following purification by flash column chromatography, 3.9 was 
dimethylated by an Eschweiler-Clarke reaction using sodium cyanoborohydride and 
formaldehyde to produce 3.10. The final synthetic step requires methylation of the 
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dimethylamine with the strong methylating agent, methyl trifluoromethanesulfonate 
(MeOTf). The resulting 6-trimethylamino-2-ethylnaphthoate trifluoromethanesulfonate 
(3.11) was obtained as a pure white powder after precipitation and recrystallization. The 
identity of the product was confirmed by proton and carbon NMR spectroscopy as well as 
mass spectrometry. This prosthetic group was designed to undergo nucleophilic aromatic 
substitution in the presence nucleophilic fluorine. The electron withdrawing nature of the 
ethyl ester at carbon-2 activates the ring for nucleophilic attack by fluorine at carbon-6. 
The trimethylammonium acts as a better quality leaving group resulting in a substitution 
with fluorine. Therefore, employment of the standard radiofluorination protocols using 
potassium carbonate and kryptofix 2.2.2 was expected to be suitable for radiolabelling of 
this prosthetic group. 
 
Scheme 3.1 Synthesis of 6-trimethylamino-2-ethyl-naphthoate triflate (3.11) 
Most fluorine-18-labelled prosthetic groups reported in the literature are designed as 
activated esters for facile acylation to peptide targeting entities. The most common 
activated ester reported is the N-hydroxysuccinimide ester used for 4-[18F]-fluorobenzoic 
acid to result in N-succinimidyl-4-[18F]-fluorobenzoate. Unfortunately, acylation of our 
lead peptide analogue with an N-hydroxysuccinimide ester of 6-fluoro-2-napthoic acid 
resulted in degradation of the active ester due to harsh conditions. The sluggish and low 
yielding reactions therefore led us to seek out a different active ester. Pentafluorophenyl 
(PFP) esters are becoming recognized for the increased stability and reaction rate when 
compared to NHS esters.24, 25  
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Scheme 3.2 Synthesis of the non-radioactive standard 6-fluoro-2-pentafluorophenyl naphthoate (PFPN, 
3.13) 
A non-radioactive 6-fluoro-2-pentafluorophenylnaphthoate ([19F]-PFPN) standard was 
synthesized using 6-fluoro-2-napthoic acid, pentafluorophenol and DMAP. The desired 
activated ester was purified by flash column chromatography in an 86% yield and 
verified by 1H NMR, 13C NMR spectroscopy and high-resolution mass spectrometry 
(HRMS). A peptide precursor of 3.7 was synthesized to possess a free amine at the Dpr 
residue in position 3. This peptide was synthesized on Rink Amide MBHA resin with all 
amino acids bearing standard protecting groups. Upon cleavage from the resin using 
strong acid, all the protecting groups were removed leaving one primary amine at 
position 3 and a secondary amine on the N-terminus. This peptide precursor (3.17) is 
capable to coupling to PFPN in the presence of a weak base producing the desired 
radiolabelled ghrelin(1-8) peptide. 
3.2.3 Radiochemistry 
Full synthesis of [18F]-3.7 was carried out in 4 synthetic steps summarized in scheme 3.3. 
The first two steps were carried out on the automated Tracer Lab FXFN synthesis box. 
Shown in Figure 4, the configuration of the synthesis box was slightly modified to 
accommodate the first two synthetic steps. Valve 14 (V14) was directly attached to a 
product output line to bypass the rest of the synthesis system and transfer the crude 
reaction material from the reaction vial to a product vial outside the synthesis box for 
further manipulation. 
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Scheme 3.3 The radiosynthetic pathway for the synthesis of [18F]-PFPN by automated and manual 
synthesis. 
 
Figure 3.4 The modified schematic of Tracer Lab FXFN for the synthesis of 6-[18F]-fluoro-2-naphthoic 
acid (3.15). 
The TracerLab FXFN was prepared for synthesis by filling vial 1 with a solution of 2 mg 
potassium carbonate and 7 mg of kryptofix 2.2.2 in 200 µL of milliQ water and 800 µL of 
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acetonitrile (ACN). Vials 2 and 3 were filled with 1 mL of dry ACN each, used to 
azeotropically dry the nucleophilic fluoride-18. 2 mg of precursor 3.11 was added to vial 
4 in 750 µL of dry dimethylsulfoxide (DMSO). Finally, vial 5 contained 20 µL of 1M 
tetramethylammonium hydroxide (in water, TMAH) in 1 mL of ACN for deprotection of 
the ethyl ester. 
Fluorine-18 was delivered to the synthesis box in H2[18O] and trapped on a Waters QMA 
Carbonate Sep Pak. The activity was then eluted into the reaction vial by the solution in 
vial 1. The solution was then azeotropically dried for 5 minutes at 75°C with the solution 
in vial 2 and repeated for vial 3. Following drying, precursor 3.11 was introduced to the 
reaction vial from vial 4 and allowed to react at 110°C for 10 minutes resulting in 6-[18F]-
2-ethylnaphoate (3.14). 1M TMAH (20 µL) in 1 mL of ACN was then added to the 
reaction mixture from vial 5 and heated to 90 °C for 10 minutes. After cooling the 
reaction mixture to 40 °C, the reaction crude was then transferred from the reaction vial 
to a product vial containing 7 mL of milliQ water and 0.1% TFA in the side chamber via 
valve 14. The following steps were carried out manually. The diluted reaction crude was 
loaded onto a tC18 Sep Pak to remove any unreacted nucleophilic fluorine-18. 6-[18F]-4-
Naphthoic acid (3.15) was eluted from the tC18 Sep Pak with 1 mL of acetonitrile into a 
reaction vial containing 20 mg of pentafluorophenol, 10 mg 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) and 1 mg 4-dimethylaminopyridine (DMAP). 
The reaction mixture was allowed to sit at room temperature for 5 minutes at which time 
1 mL of milliQ water was added to the crude reaction mixture. The diluted mixture is 
then purified by semi-preparative HPLC (55 – 95% acetonitrile in water) to collect the 
pure 6-[18F]-2-pentafluorophenylnaphthoate in 6.5% decay corrected yield. The purified 
3.16 was redissolved in 1 mL of acetonitrile containing 1.5 mg of peptide precursor 
(3.17) (Scheme 3.4). After administration of 30 µL of diisopropylethylamine (DIPEA), 
the reaction mixture was warmed at 40 °C for 20 minutes before being diluted with 500 
µL milliQ water and purified by semi-preparative HPLC (20 – 80% acetonitrile in water). 
HPLC purified [18F]3.7 was collected at 5 minutes in a 3.1% decay corrected yield. The 
identity of 3.18 was confirmed by co-injection with the non-radioactive standard 3.7 
(Figure 3.5). 
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Scheme 3.4 Coupling of [18F]-PFPN to the lead ghrelin(1-8) analogue resulting in [18F]-3.7.  
 
Figure 3.5 Overlaid C18 reverse-phase HPLC chromatograms of [19F]-3.7 (AU) and [18F]-3.7 (mV).  
3.2.4 Conclusions 
Ghrelin has shown it is capable of distinguishing between cancerous and benign prostate 
tissue that has shown to be a difficult task with other clinical PET imaging agents, such 
as [18F]-fluorodeoxyglucose. This emphasizes the need for new ghrelin-based PET 
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probes. The natural ghrelin(1-8) sequence was methodically altered to increase the 
affinity to GHS-R1a from 200 nM to 0.16 nM. Modifications made at positions 1, 3, 4 
and 8 resulted in various analogues with IC50 values equal or better than ghrelin(1-28). 
Compiling all the lead modifications into one peptide analogue resulted in [Inp1, Dpr3(6-
fluoro-2-naphthoate), 1-Nal4, Thr8] ghrelin(1-8) which possessed a fluorine for further 
development into a PET radiopeptide. 3.7 resulted in a 1250-fold increase of affinity to 
GHS-R1a than 3.3 based off their IC50 values. In order to incorporate fluorine-18, a new 
prosthetic group, [18F]-PFPN, was developed using a combination of automated and 
manual synthesis with a TracerLab FXFN synthesis box. Coupling of [18F]-PFPN to the 
lead peptide analogue with a free amine at residue 3 resulted in the first fluorine-18 
labelled, high affinity ghrelin (1-8) analogue for GHS-R1a in an overall 3.1% 
radiochemical yield (d.c.). Therefore, this reports the successful radiolabelling of the first 
fluorine-18 labelled ghrelin(1-8) analogue. This is not only the highest affinity ghrelin 
analogue reported in the literature, it is also the shortest ghrelin analogue capable of 
binding GHS-R1a with better affinity than ghrelin(1-28). 
Preclinical evaluation of this PET probe is currently underway in prostate cancer models 
although [18F]-3.7 can be a valuable tool for visualizing various tissues and disease states 
that are known for GHS-R1a expression beyond the field of oncology. 
3.3 Experimental 
3.3.1 Materials and Methods 
All common solvents were purchased from Fisher Scientific. All protected amino acids, 
coupling reagents and resins were purchased from Novabiochem, Peptides International 
and Chem-Impex and were used without further purification unless otherwise stated. All 
reagents were obtained from Sigma-Aldrich. RP-tC18 Sep-Pak SPE and QMA carbonate 
SPE cartridges were purchased from Waters. [125I]-Ghrelin was purchased from Perkin 
Elmer. Cyclotron produced [18F]H218O was obtained from Dr. Mike Kovacs at the 
Cyclotron & PET Radiochemistry Facility at St. Josephs Hospital in London, Ontario, 
Canada. For analytical HPLC-MS, a Agilent RP-C18 4.6 x 250 mm, 5 µm column was 
used. For semi-preparative HPLC-MS work, an Agilent RP-C18 19 x 150 mm, 5 µm 
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column was used. A gradient solvent system was used containing 0.1% TFA in 
acetonitrile (solvent A) and 0.1% TFA in water (solvent B). For analytical UHPLC-MS, 
studies were performed on a Waters, Inc. Acquity UHPLC H-Class system, combined 
with a Xevo QTof mass spectrometer (ES+, cone voltage = 30 V). For analytical 
UHPLC-MS studies, a Waters Acquity UHPLC BEH C18 2.1 x 50 mm, 1.7 µm column 
was used with a gradient solvent system consisting of 0.1% formic acid in acetonitrile 
(solvent C) and 0.1% formic acid in water (solvent D). Analytical radio-RP-HPLC 
(AgilentTM RP-C18 column 4.6 x 150 mm, 5 µm) was performed on a Waters 1525 
Binary HPLC pump containing a Waters 2487 dual λ absorbance detector, Waters In-
Line degasser, a gamma detector and Breeze software (version 3.30). 
3.3.2 General FMOC Synthesis of Ghrelin(1-8) Peptides 
Peptide synthesis was carried out manually using FMOC-based solid-phase peptide 
chemistry. Peptides were synthesized at a 0.1 mmol scale on Rink Amide MBHA resin 
(0.52 mmol/g). The resin was initially swelled with N,N-dimethylformamide (DMF), 
followed by Fmoc deprotection using 2 mL of 20% piperidine in N,N-dimethylformamide 
(DMF) for two cycles (10 minutes, 5 minutes). Amino acids were preactivated by 
combining 3 eq. of Fmoc-protected amino acid, 3 eq. of O-(6-chlorobenzotriazol-1-yl)-
N,N,N’,N’-tetramethyluronium hexafluorophosphate (HCTU) and 6 eq. of N,N-
diisopropylethylamine (DIPEA) in 2 mL of DMF. The mixture was added to the resin 
and vortexed for 60 minutes. These cycles were repeated until all 8 N-terminal amino 
acids were coupled to the resin. 
Allyloxycarbonyl deprotection of diaminopropionic acid was performed under inert 
atmospheric N2 conditions. DCM was dried over sieves for 24 hours before adding 1 mL 
to the resin. 2 eq. of phenylsilane in 1 mL dry DCM was then added to the peptide resin 
followed by 0.045 eq. of tetrakis(triphenylphosphine) palladium (0) in 1 mL dry DCM. 
The peptide vessel was removed from inert conditions and allowed to react for 30 
minutes. The resulting free amine was acylated using 2 eq. of the corresponding acid 
(octanoic acid, 4-fluorobenzoic acid, 6-fluoronaphthoic acid or 4’-fluoro-[1,1’-biphenyl]-
4-carboxylic acid), 2 eq. of HCTU and 6 eq. of DIPEA in DMF. The reaction mixture 
was left to couple overnight.  
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Full deprotection of the synthesized peptide was performed by adding a 2 mL mixture of 
95% trifluoroacetic acid (TFA), 2.5% triisopropylsilane (TIS) and 2.5% water to the resin 
and allowed it to mix for 5 hours. The cleaved peptide was precipitated from solution 
using ice-cold tert-butyl methyl ether (TBME) and centrifuged (3000 rpm, 10 minutes) 
resulting in a crude peptide pellet. The supernatant was decanted and the resulting peptide 
pellet was dissolved in 20% acetonitrile in water, frozen at -78 °C and lyophilized to a 
white crude powder. Purification was performed using preparative HPLC-MS and purity 
of the resulting peptides were analyzed using analytical UHPLC, these results are 
summarized in table 3.4. 
Table 3.4 Analytical data of ghrelin analogues 3.3-3.3j, 3.4a-3.4b, 3.5a-3.5c, 3.6a-3.6b and 3.7 
 
3.3.3 Competitive Binding Assay (IC50) 
The affinity for GHS-R1a was determined using a radioligand competitive binding assay. 
Assays were performed using GHS-R1a transfected HEK293 cells as receptor source and 
human [125I]-ghrelin(1-28)  (PerkinElmer Inc.) as the radioligand. Human ghrelin(1-28) 
was used as reference to ensure the validity of the results. A suspension of membrane 
from HEK293/GHS-R1a cells (50,000 cells per assay tube) were incubated with 
ghrelin(1-8) peptide analogues (at concentrations of 10-5 M, 10-6 M, 10-7 M, 10-8 M, 10-9 
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M, 10-10 M and 10-11 M) and [125I]-ghrelin (15 pM per assay tube) in binding buffer (25 
mM HEPES, 5 mM magnesium chloride, 1 mM calcium chloride, 2.5 mM EDTA, and 
0.4% BSA, pH 7.4). The resulting suspension was incubated for 20 minutes under 
shaking (550 rpm) at 37 °C. Unbound [125I]-ghrelin was removed and the amount of 
[125I]-ghrelin bound to the membranes was measured by gamma counter. IC50 values 
were determined by nonlinear regression analysis to fit a 4 parameter dose response curve 
using Prism 6 (Version 6.0c). All binding assays were performed in triplicate. 
3.3.4 Synthesis of 6-amino-2-ethylnaphthoate (3.9) 
6-Amino-2-naphthoic acid (300 mg, 1.60 mmol) was dissolved in 50 mL of ethanol and 
heated to 80 °C while stirring in a 100 mL round bottom.  Sulfuric acid was added 
dropwise until pH 6 was reached. The reaction was left to reflux overnight. Ethanol was 
removed by rotary evaporation and the crude oil was redissolved in dichloromethane and 
transferred to a separatory funnel. Compound 3.9 was extracted with 0.1 M sodium 
bicarbonate (50 mL) and dichloromethane (3 x 50 mL). The organic fractions were 
combined and dried with MgSO4. MgSO4 was removed by gravity filtration and the 
resulting solution was removed by rotary evaporation. The crude solid was dissolved in 1 
mL of dichloromethane with 0.1 % triethylamine. The crude solution was purified by 
flash column chromatography (dichloromethane, 0.1% triethylamine) and tracked by 
TLC. The spot at Rf = 0.4 was collected into a 100 mL round bottom and rotary 
evaporated to dryness. Pure 3.9 was isolated as a brown solid in 86% yield (295 mg, 1.37 
mmol). HRMS: m/z calculated for C13H13O2N, 215.0946; observed 215.0942. 1H-NMR 
Spectrum (400 MHz, CDCl3, δ): 8.46 (1H, s, Harom), 7.96 (1H, d, Harom, J = 8 Hz), 7.77 
(1H, d, Harom, J = 12 Hz), 7.60 (1H, d, Harom, J = 12 Hz), 7.00-6.97 (2H, m, Harom), 4.42 
(2H, q, CH2CH3, J = 8 Hz), 1.43 (3H, t, CH2CH3).  
3.3.5 Synthesis of 6-dimethylamino-2-ethylnaphthoate (3.10) 
Compound 3.9 (295 mg, 1.37 mmol) was dissolved in 60 mL of methanol in a 250 mL 
round bottom and stirred at room temperature. While stirring, 37 %wt formaldehyde (2.0 
mL, 27.4 mmol) was added dropwise followed by sodium cyanoborohydride (0.86 g, 
13.7 mmol) and was left to stir at room temperature for 12 hours. After 12 hours, starting 
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material was still present by thin layer chromatography (TLC) (100% dichloromethane), 
therefore the reaction was heated to 40 °C for 4 hours. The reaction mixture was diluted 
with 50 mL of fresh dichloromethane and transferred to a separatory funnel. The crude 
product was extracted with distilled water (50 mL) and dichloromethane (3 x 50 mL). 
The organic fractions were combined and dried with MgSO4. MgSO4 was removed by 
gravity filtration and the resulting solution was removed by rotary evaporation to a 
yellow solid and dried under high vacuum. The crude solid was dissolved in 1 mL of 
10% hexanes in dichloromethane and purified by flash column chromatography (10% 
hexanes in dichloromethane) and tracked by TLC. Fractions containing the spot at Rf = 
0.55 were combined into a 100 mL round bottom and rotary evaporated. Pure 3.10 was 
obtained in 64% yield (213 mg, 0.87 mmol). HRMS: m/z calculated for C15H17O2N, 
243.1259; observed 243.1255. 1H-NMR Spectrum (400 MHz, CDCl3, δ): 8.40 (1H, s, 
Carom), 7.92 (1H, d, J= 8 Hz, Carom), 7.81 (1H, d, J= 8 Hz, Carom), 7.70 (1H, d, J= 8 Hz, 
Carom), 7.28 (1H, d, J= 8 Hz, Carom)  6.96 (1H, s, Carom), 4.33 (2H, q, J = 8 Hz, CH2CH3). 
3.06 (6H, s, (CH3)2), 1.35 (3H, t, J = 8 Hz, CH2CH3). 
3.3.6 Synthesis of 6-trimethylamino-2-ethylnaphthoate triflate 
(3.11) 
Compound 3.10 (200 mg, 0.82 mmol) was dissolved in 30 mL of anhydrous 
dichloromethane dried over sieves. The round bottom was evacuated and charged with 
N2. The reaction mixture was then cooled to 0 °C in an ice bath and methyl 
trifluoromethansulfonate (370 µL, 3.28 mmol) was added dropwise using an oven dried 
needle and syringe. The reaction was left to stir. Pure 3.11 precipitated out of solution 
after 1 hour. The precipitate was collected with a Hirsch funnel and rinsed thoroughly 
with cold anhydrous dicholoromethane. The resulting white solid was dried under high 
vacuum, with 3.11 being isolated in a 78% yield (260 mg, 0.64 mmol). 1H-NMR 
Spectrum (400 MHz, DMSO, δ): 8.77 (1H, s, Carom), 8.62 (1H, s, Carom), 8.47 (1H, d, J= 8 
Hz, Carom), 8.17-8.26 (3H, m, Carom), 4.40 (2H, q, J= 8 Hz, CH2CH3)  3.72 (9H, s, (CH3)3), 
1.38 (3H, t, J = 8 Hz, CH2CH3). 13C-NMR Spectrum (100 MHz, DMSO, δ): 223.0 (Carom-
N(CH3)3), 165.9 (C=O), 134.7 (Carom), 132.3 (Carom), 132.1 (Carom), 130.0 (Carom), 130.0 
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(Carom), 127.0 (Carom), 120.0 (Carom), 120.0 (Carom), 110.0 (Carom), 62.9 (N-(CH3)3), 61.6 
(CH2CH3), 21.4 (CH2CH3). 
3.3.7 Synthesis of [19F]-PFPN 
6-Fluoronaphthoic acid (200 mg, 1.05 mmol) and pentafluorophenol (211 mg, 1.15 
mmol) were dissolved in 100 mL of dichloromethane and cooled to 0 °C in an ice bath. 
EDC (30.2 mg, 1.58 mmol) and DMAP (25 mg, 0.21 mmol) were added to the reaction 
and stirred. The reaction was tracked by thin-layer chromatography (5% ethyl acetate in 
hexanes, Rf = 0.69).  After 1 hour, no starting material was visible by TLC. The reaction 
was quenched with 30 mL of saturated ammonium chloride (NH4Cl) and transferred to a 
250 mL separatory funnel. [19F]-PFPN was extracted with 50 mL of ethyl acetate and 
repeated 3 times. The organic layers were combined and dried with magnesium sulphate 
(MgSO4). MgSO4 was removed by gravity filtration and the solution was dried using 
rotary evaporation.  The crude solid was dissolved in 1 mL of 5% ethyl acetate in 
hexanes and loaded onto a silica plug and eluted with 5% ethyl acetate in hexanes. [19F]-
PFPN was isolated as a white solid in 86% yield (322 mg, 0.90 mmol). HRMS: m/z 
calculated for C17H6O2F6, 356.0272; observed 356.0279. 1H-NMR Spectrum (400 MHz, 
CDCl3, δ): 8.81 (1H, s, Harom), 8.19 (1H, d, Harom, J = 8 Hz), 8.04 (1H, dd, Harom, J = 8 Hz, 
2 Hz), 7.93 (1H, d, Harom, J = 8 Hz), 7.57 (1H, d, Harom, J = 8 Hz), 7.41 (1H, dd, Harom, J = 
8 Hz, 2 Hz)  13C-NMR Spectrum (100 MHz, CDCl3, δ): 163.9 (C=O), 162.7 (F-Cnaphthyl), 
161.4 ((C=O)O-C6F5), 137.5 (C6F5), 137.4 (C6F5), 132.9 (C6F5), 132.4 (C6F5), 132.3 
(C6F5), 129.4 (Cnaphthyl), 128.2 (Cnaphthyl), 128.1 (Cnaphthyl), 126.4 (Cnaphthyl), 123.5 (Cnaphthyl), 
118.0 (Cnaphthyl), 117.7 (Cnaphthyl), 111.5 (Cnaphthyl), 111.2 (Cnaphthyl). 
3.3.8 Radiolabelling Procedure of [18F]-PFPN 
To prepare 3.11, Tracerlab FXFN (GE Healthcare) was configured as shown in figure 4. 
Vials were loaded as follows: Vial 1: potassium carbonate (2.0 mg), krytofix 2.2.2 (7.0 
mg) in 200 µL H2O and 800 µL ACN; Vial 2: 1000 µL anhydrous ACN; Vial 3: 1000 µL 
anhydrous ACN; Vial 4: 2 mg of 3.11 in 750 µL DMSO; Vial 5: 20 µL TMAH (1M) in 
1000 µL ACN.  
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Fluorine-18 was produced on a GE Healthcare PETtrace 880 cyclotron (16.5 MeV) via a 
18O(p,n) nuclear reaction on a high yield Nb25 fluorine-18 target. Fluoride-18 was 
delivered in a 2 mL aliquot to a QMA carbonate Sep-Pak to isolate the [18O]H2O from 
fluoride-18. The fluoride was then eluted into the reaction vial using the potassium 
carbonate/kryptofix solution in Vial 1. The fluoride-18 was azeotropically dried by 
heating the reaction vial to 75 °C under full vacuum for 5 minutes. This repeated 2 more 
times using the anhydrous ACN in Vials 2 and 3. Once dried, the radiolabelling precursor 
3.11 was added to the reaction vial from Vial 4, heated to 120 °C and allowed to react for 
10 minutes. Following this reaction, Vial 5 was added to the reaction vial to hydrolyze 
the ester, heated to 90 °C for 5 minutes before being cooled to 40 °C and completing the 
automated portion of the synthesis. The reactor needle was injected down into the 
reaction mixture and helium was pumped into the reaction vial for 3 minutes to transfer 
the crude mixture from the reaction vial to a product vial via V14.The crude mixture was 
collected into 20 mL scintillation vial containing 7 mL of 0.1% TFA in MilliQ water in 
the side chamber and removed for manual synthesis. 
The diluted mixture was loaded onto a conditioned tC18 Sep Pak to remove unreacted 
fluoride-18. Radiolabelled 3.16 was eluted from the Sep-Pak with 1000 µL of ACN into a 
new reaction vial containing 20 mg pentafluorophenol, 10 mg EDC and 1 mg of DMAP. 
The mixture was allowed to react at room temperature for 5 minutes before being diluted 
with 500 µL of 0.1% TFA in H2O and injected onto the HPLC for semi-preparative 
purification (55% to 95% acetonitrile in water with 0.1% TFA). Purified 3.16 was 
collected at 9 minutes into a scintillation vial and subsequently evaporated to dryness 
using a Biotage Speed Rotary Evaporator for 5 minutes. After evaporation, 3.17 in 750 
µL of ACN was added to the scintillation vial followed by 30 µL of DIPEA. The reaction 
mixture was left at 40 °C for 20 minutes, diluted to 1500 µL with 0.1% TFA in H2O and 
injected on to the HPLC for semi-preparative purification (20% to 80% acetonitrile in 
water with 0.1% TFA). Purified 3.18 was collected at 5 minutes for 1.5 minutes into a 10 
mL sterile vial resulting in approximately 8 mL of solvent. 
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3.3.9 Quality Control of [19F]-PFPN 
Using an analytical radio-RP-HPLC equipped with a gamma detector, the radiochemical 
purity and identity of 3.18 was confirmed by co-injection with a non-radioactive standard 
3.7. Retention times were consistent at 5.0 minutes. 3.18 was obtained in 3.1% decay 
correct radiochemical yield and 95% radiochemical purity with a complete synthesis time 
of 1.5 hours. 
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Chapter 4 
4 Synthesis of Monomeric and Dimeric Dye Labelled 
Ghrelin(1-8) Analogues for Evaluation in GHS-R1a 
Expressing Cells by Fluorescence Microscopy 
4.1 Introduction 
The growth hormone secretagogue receptor-1a (GHS-R1a) is a G-protein coupled 
receptor (GPCR) that is activated by peptidic growth hormone secretagogues to release 
growth hormone from the pituitary. This receptor is not solely expressed in the pituitary 
and can be found in various other tissues such as the hypothalamus, heart, lung, pancreas, 
intestine and adipose.1, 2 When activated by its endogenous ligand, ghrelin, this receptor 
performs important roles such as energy homeostasis, body weight control, aging and 
cardiac contractility. The endogenous ligand for GHS-R1a was isolated from the rat 
stomach in 1990 by Kojima et. al.2 Ghrelin is a 28 amino acid peptide containing a 
unique octanoylated serine at residue 3 of the amino acid sequence.  
Several peptides, such as neuropeptide Y, cholestokinin and ghrelin, are capable of 
stimulating feeding and maintaining a positive energy balance through central or 
peripheral administered doses.3-5 What is most intriguing about ghrelin, is its ability to 
have a longer acting regulation of body weight rather than a short-term, meal related 
regulation found with other peptides, such as cholestokinin. The ghrelin-GHSR-1a axis 
has also been implicated in aging. Studies have shown the GHS-R1a regulates the timing 
and amplitude of growth hormone release in human subjects and as subjects age, the 
amplitude of growth hormone release begins to regress. Administration of ghrelin agonist 
analogues to elderly human subjects was shown to increase amplitude of GH release, 
increase lean mass in shoulder and knee strength, accelerate the healing process 
following a hip fracture as well as increase bone mineral density in postmenopausal 
women.6-10 From a therapeutic standpoint, targeting GHS-R1a receptors using ghrelin-
based analogues can hold promise for treatment of anorexia, cachexia or other diseases 
that cause involuntary weight loss as well as age-dependent functions caused by 
suppression of growth hormone.11 Targeting of GHS-R1a is also advantageous for 
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diagnosis of cardiomyopathy and cancer. Studies have shown that GHS-R1a is 
upregulated in the left ventricular tissue of patients that previously suffered congestive 
heart failure. These areas of higher GHS-R1a concentration were visualized using dye-
labelled ghrelin analogues and fluorescence microscopy.12-14 GHSR-1a and ghrelin have 
also been implicated in many cancer progression processes such as cell proliferation, 
migration and apoptosis. GHSR-1a has been identified in a wide range of human cancers 
such as pituitary, prostate, breast, and ovarian tumours as well as astrocytoma.15 The 
GHS-R1a/ghrelin axis plays an important role in various biological issues that require 
therapeutic and diagnostic pharmceuticals. Development of ghrelin-based ligands with 
affinity and specificity to GHS-R1a would have a wide range of applications in both 
therapeutic and diagnostic fields.  
There are several approaches to increasing the affinity and specificity of a targeting 
ligand, one method that has proven to be successful is multimerization. Several examples 
of multimerization have been demonstrated with RGD to target the integrin receptor αvβ3. 
When compared to monomeric RGD, dimeric and tetrameric analogues have shown to 
possess improved in vivo kinetics and target affinity.16, 17 The increase in affinity has been 
attributed to a higher local concentration of the targeting peptide in the immediate 
surroundings of the receptor. Once one unit of the multimer ligand has been bound, the 
other units are more likely to have a higher rate of binding and lower rate of dissociation. 
This phenomenon leads to higher uptake and longer retention of targeting ligands at the 
receptor.18 These aspects of multimerization are valuable when visualizing receptors of 
interest and therefore have been applied to various peptides used in optical imaging and 
scintillation imaging.16-22 
Optical imaging (OI) is a useful tool to visualize molecular targets in living systems 
without using radioactive materials required for other imaging modalities, such as 
positron emission tomography (PET) and single-photon emission computed tomography 
(SPECT). This method of imaging is known to be a cost-effective and robust but 
difficulties arise when photons are absorbed or scattered by surrounding tissues. These 
difficulties can be addressed by using near-infrared (NIR) light (700-1000 nm) that has 
better photon penetration in and out of tissues and therefore more less absorption and 
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scattering is caused by tissues. OI can be used to better understand the biology of various 
disease states as well as monitor therapy and other biological process. 
There are two examples in which fluorescently labelled ghrelin analogues have been used 
to detect the GHS-R1a receptor as a biomarker of prostate cancer and cardiomyopathy.13, 
23 In the first example, a fluorescein-ghrelin(1-19) analogue was incubated with prostate 
core biopsy samples of 13 patients with ranging conditions from normal, benign 
hyperplasia (BPH), prostatic interneoplasia (PIN) and prostate cancer. Using OI, the 
fluorescent signal of fluorescein-ghrelin(1-19) was 4.7-fold higher in prostate cancer than 
BPH and normal prostate tissue. The signal was also 1.9-fold higher in prostate cancer 
than PIN. This not only demonstrates the value OI agents have for biomarker screening 
of ex vivo biopsy samples using a facile and low cost method of detection, but also 
demonstrates the usefulness of ghrelin for accurate detection of prostate cancer from 
other states of prostate tissue health. The second example uses a Cyanine5-ghrelin(1-19) 
analogue to detect the presence of GHS-R1a during the differentiation of P19-derived 
cardiomyocytes through using OI in in vitro and ex vivo assays. 
In this study, we propose to synthesize high affinity monomeric and dimeric ghrelin(1-
10) analogues bearing a NIR Cyanine5 dye. These NIR-analogues can be used to 
visualize GHS-R1a using flourescence microscopy and holds promise for monitoring 
therapies and diagnosis of the various biological processes effected by the GHS-R1a 
receptor. 
4.2 Results and Discussion 
4.2.1 Synthesis and Characterization of a NIR Ghrelin(1-10) 
Monomer and Dimer 
As discussed in Chapter 3, ghrelin can be truncated to the first 8 N-terminal amino acids 
and maintain affinity to GHS-R1a. Through modification of various positions in the 8 
amino acid sequence, several analogues were able to selectively target GHS-R1a with 
remarkable affinity. Replacing phenylalanine-4 with 1-naphthylalanine (Nal-1) lead to a 
48-fold increase in affinity to GHS-R1a while replacing glutamic acid-8 with threonine 
lead to a 61-fold increase in affinity than the natural ghrelin(1-8) sequence. These two 
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modifications were incorporated into a ghrelin(1-10) monomer and a ghrelin (1-10) dimer 
to target GHS-R1a. All the other amino acids were left unchanged except for residue 3, 
which was substituted for diaminopropionic acid (Dpr) acylated with octanoic acid. This 
substitution replaces the labile ester moeity with an amide for better stability and facile 
chemical synthesis. Therefore, the ghrelin(1-8) peptide chosen to be further developed 
into a fluorescent ghrelin(1-10) monomer and dimer was; H-GS-Dpr(octanoyl)-(Nal-1)-
LSPT-NH2.  
 In order to maintain affinity to GHS-R1a, ghrelin analogues can only be modified 
at the C-terminus due to the importance of the N-terminal amine for receptor binding.24 
The Cy5-Ghrelin (1-10) monomer (Scheme 4.1) and dimer (Scheme 4.2) were 
synthesized using standard Fmoc peptide chemistry on a solid supprt. They were 
synthesized with amino acids bearing standard protecting groups, with the exception of 
Dpr and Lys, that contained the orthogonal protecting groups methytrityl (Mtt) and 
allyloxycarbonyl (Alloc). After automated peptide synthesis of the core amino acid 
sequence, the orthogonal protecting groups were selectively removed to acetylate Dpr 
with octanoic acid and to incorporate the cyanine-5 (Cy5) on the lysine side chain, 
resulting in the 4.4. To synthesize the ghrelin dimer, the first ghrelin unit was synthesized 
on solid support using automated peptide synthesis followed by selective deprotection of 
the lysine alloc protecting group to couple another Fmoc-lysine(alloc)-OH using standard 
coupling conditions. The second lysine introduces another Fmoc-protected N-terminal 
amine for the second targeting ghrelin unit to be synthesized using automated peptide 
synthesis. Once both ghrelin units were added to the solid support, the Mtt protecting 
group is selectively deprotected from both Dpr side chains and the resulting free amines 
are acylated with octanoic acid. The final deprotection of alloc on the second lysine side 
chain leaves a free amine to couple Cy5 resulting in 4.10. To reduce the negative steric 
effects the Cy5 may cause on receptor affinity, the ghrelin(1-8) targeting peptides were 
separated from the lysine by a [2-(2-(Fmoc-amino)ethoxy)ethoxy]acetic acid (AEEA) 
spacer and are therefore ghrelin(1-10) analogues. Both peptides were cleaved from the 
resin and all standard protecting groups removed using strong acid before being purified 
by reverse-phase preparative HPLC. The yeilds and purities are summarized in Table 1. 
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Table 4.1 Analytical data for 4.4 and 4.10 
Ghrelin 
Analogue 
[M+2H]2+ 
Expected 
[M+2H]2+ 
Observed 
Yield Purity 
4.4 934.4612 934.1838 26% 98% 
4.10 1547.3027 1547.9197 25% 91% 
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Scheme 4.1 Synthesis of monomer (4.4). a. 2% TFA, 5% TIS in DCM, b. octanoic acid (3 eq.), 
HCTU (3eq.), DIPEA (6 eq.) c. Pd(PPH3)4 (0.035 eq.), PhSiH3 (2 eq.), DCM, d. sulfo-Cy5 NHS 
ester (1 eq.), DIPEA (2 eq.) in DMF, e. 95% TFA, 2.5% H2O, 2.5% TIS 
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Scheme 4.2 Synthesis of dimer (4.10). f. Pd(PPH3)4 (0.035 eq.), PhSiH3 (2 eq.), DCM, g. Fmoc-
Lys(alloc)-OH (3 eq.), HCTU (3 eq.), DIPEA (6 eq.) in DMF, h. 20% piperidine in DMF (3 mL), i. 
Automated peptide synthesis, j. 2% TFA, 2% TIS in DCM, k. octanoic acid (6 eq.), HCTU (6 eq.), 
DIPEA (12 eq.) l. Pd(PPH3)4 (0.035 eq.), PhSiH3 (2 eq.), DCM, m. sulfo-Cy5 NHS ester (1 eq.), DIPEA 
(2 eq.) in DMF, n. 95% TFA, 2.5% H2O, 2.5% TIS 
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4.2.2 Binding Affinity of 4.4 and 4.10 to GHS-R1a 
The binding affinity of each peptide was measured using a competitive binding assay 
against 125I-Ghrelin(1-28). Varying concentrations of the monomer and dimer were 
incubated with HEK293 cells transfected with GHS-R1a in the presence of 125I-ghrelin(1-
28). As the concentration of the monomer and dimer was increased, 125I-ghrelin(1-28) 
was competitively displaced and quantified into sigmoidal curve (Figure 4.2). The half-
maximal concentration (IC50) can be extracted from these curves and used to quantify the 
binding affinity to GHS-R1a.  
From the IC50 curves, the monomer (4.4) had 26.3 nM affinity while the dimer (4.10) had 
50.0 nM affinity. As reported in Chapter 2, the IC50 of the unmodified ghrelin(1-8) 
sequence is 200 nM. The monomer and dimer were able to achieve 7.6 and 4.0-fold 
increase in affinity, respectively. This is the opposite trend than expected. Dijkgraff et al. 
studied the multimerization of [68Ga]-RDG peptides by synthesizing a homomonomer, 
dimer and tetramer. The binding affinity to integrin αvβ3 became stronger as more RGD 
units were added. The monomer, dimer and tetramer had IC50 values of 23.9 nM, 8.99 nM 
and 1.74 nM respectively. Multimerization of ghrelin did not produce the same trend 
although tetrameric analogues were not studied.21 
 
 
Figure 4.1 Competitive binding curves in HEK293/GHS-R1a cells and IC50 (nM) values for 4.4 (A) and 
4.10 (B) 
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4.2.3 In Vitro Fluorescence Imaging in HT1080 and HT1080/GHS-
R1a 
The subcellular localization of 4.4 and 4.10 were evaluated in the HT1080 (GHS-R1a 
negative) cell line and the HT1080/GHS-R1a (GHS-R1a positive) cell line. Each peptide 
was diluted with DMSO into a 0.5 µM solution and incubated with each cell line for 1 
hour at 37 °C. The cells were then rinsed with serum-free media and PBS before fixed to 
microscope slides with 4% paraformaldehyde. Cyanine5 has an excitation maximum of 
646 nm and emission maximum of 662 nm, therefore the slides were irradiated with 636 
nm light for excitation and emissions were collected using a 663-738 nm filter to 
visualize the dye-labelled fluorescence. DAPI stained nuclei were irradiated with 402 nm 
light and emissions were collected using a 425 – 475 nm filter. The images were then 
overlaid into the merge images. 
 
Figure 4.2 Confocal microscopy results of 4.4 and 4.10 with HT1080 (GHS-R1a negative) and 
HT1080/GHS-R1a (GHS-R1a positive) (magnification x 60). 
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The obtained fluorscence images are shown in Figure 4.2. Contrary to the IC50 results, 4.4 
had little localization in both cell lines. Within the HT1080/GHS-R1a images, it appears 
that there are areas of highly concentrated fluorescence on the cell surface that are not 
present in the HT1080 cell line. This could be due the higher expression of the target 
receptor although the difference of fluorescence in each cell line was hypothesized to be 
much greater. 4.10, which possessed the lower affinity to GHS-R1a based off the IC50 had 
high fluorescence in both cell lines. The fluorescence in HT1080 cells appears uniform 
along the cell surface while the fluorescence appears less uniform and more concentrated 
into specific areas on the cell surface of the HT1080/GHS-R1a cells. This is the same 
trend seen with 4.4. The high fluorescence of 4.10 in HT1080 cells suggest that creating a 
dimer of ghrelin has effect the in vitro properties of peptide and lead the peptide to non-
preferentially binding to the cell surface. This is undesirable as the peptide can no longer 
be used to distinguish between GHS-R1a expression. Western blot analysis is underway 
with HT1080 and HT1080/GHS-R1a cells to confirm the expression of GHS-R1a in each 
cell line. These results will provide an explanation regarding the low uptake of the 
monomer 4.4 that is unexpected with an IC50 of 25.3 nM. 
4.3 Conclusions 
The many biological roles effected by GHS-R1a make this a beneficial pharmacological 
target for various therapeutic and diagnostic applications that require specific and 
prolonged interaction of a targeting entity with the receptor. As mentioned in Chapter 2, 
ghrelin(1-8) analogues are capable of targeting GHS-R1a with high affinity and using the 
emerging field of multimerization, held promise to become higher affinity and longer 
acting ghrelin targeting entities. Unfortunately, dimerizing a high affinity ghrelin(1-8) 
analogue and introducing a NIR dye caused detrimental effects on binding affinity. The 
dimerized peptide also developed non-preferential cell surface binding when dimerized 
and therefore were not ideal OI agents for GHS-R1a. Liu et al. compared the 
pharmacokinetic properties of two RGD dimers with differing chain lengths between the 
homodimeric units. One RGD dimer contained 15 atom linker while the other RGD 
dimer contained a 47 atom linker. The extra chain length increased the in vitro binding 
affinity, but more importantly, resulted in better tumour to background ratios.19 
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Therefore, it is advantageous to further investigate the optimal chain length between 
ghrelin units in order to obtain better binding affinity and in vitro kinetics of these 
dimers.  Other structural changes such as using a different ghrelin(1-8) sequence, or 
another NIR dye may also have a positive effect on these dimer properties.  
4.4 Experimental 
4.4.1 Materials and Methods 
All common solvents were purchased from Fisher Scientific. All protected amino acids, 
coupling reagents and resins were purchased from Novabiochem, Peptides International 
and Chem-Impex and were used without further purification unless otherwise stated. All 
reagents were obtained from Sigma-Aldrich. [125I]-Ghrelin(1-28) was purchased from 
Perkin Elmer. For analytical HPLC-MS, an Agilent RP-C18 4.6 x 250 mm, 5 µm column 
was used. For semi-preparative HPLC-MS work, an Agilent RP-C18 19 x 150 mm, 5 µm 
column was used. A gradient solvent system was used containing 0.1% TFA in 
acetonitrile (solvent A) and 0.1% TFA in water (solvent B). For analytical UHPLC-MS, 
studies were performed on a Waters, Inc. Acquity UHPLC H-Class system, combined 
with a Xevo QTof mass spectrometer (ES+, cone voltage = 30 V). For analytical 
UHPLC-MS studies, a Waters Acquity UHPLC BEH C18 2.1 x 50 mm, 1.7 µm column 
was used with a gradient solvent system consisting of 0.1% formic acid in acetonitrile 
(solvent C) and 0.1% formic acid in water (solvent D). 
4.4.2 Automated Peptide Synthesis of 4.4 
Automated peptide synthesis was carried out using a Biotage Syrowave synthesizer and 
all amino acids contained standard protecting groups with the exception of Dpr and Lys 
that contained methyltrityl (Mtt) and allyloxycarbonyl (Alloc) orthogonal protecting 
groups, respectively. The N-terminal glycine contained a BOC protecting group rather 
than Fmoc. 4.4 was synthesized at a 0.1 mmol scale on Rink Amide MBHA resin (0.52 
mmol/g). The resin was initially swelled with N,N-dimethylformamide (DMF) followed 
by two cycles (10 minutes, 5 minutes) of Fmoc deprotection using 2 mL of 20% 
piperidine in N,N-dimethylformamide (DMF). Amino acids were preactivated by 
combining 3 eq. of Fmoc-protected amino acid, 3 eq. of HCTU and 6 eq. of N,N-
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diisopropylethylamine (DIPEA) in 2 mL of DMF. The mixture was added to the resin 
and coupled for 60 minutes. These cycles were repeated until all 10 N-terminal amino 
acids were coupled to the resin in the following sequence; H-GS-Dpr(mtt)-Nal-1-LSPT-
AEEA-Lys(Alloc)-Rink Amide MBHA Resin. 
Mtt deprotection of diaminopropionic acid was performed using vortexing the resin with 
2 mL of 2% TFA and %5 TIS in dichloromethane for 2 minutes. The resin was then 
rinsed well with dichloromethane. This method was repeated 8 times, or until the solution 
no longer appeared yellow. Following the deprotection, the resin was vortexed with 200 
µL of DIPEA in DMF to neutralize any residual TFA. Octanoic acid (3 eq.) was coupled 
to the Dpr free amine using HCTU (3 eq.) and DIPEA (6 eq.) in DMF. The resin was 
vortexed for 1 hour. 
Allyloxycarbonyl deprotection of lysine was performed under inert atmospheric N2 
conditions. DCM was dried over sieves for 24 hours before adding 1 mL to the resin. 2 
eq. of phenylsilane in 1 mL dry DCM was then added to the peptide resin followed by 
0.045 eq. of tetrakis(triphenylphosphine) palladium (0) in 1 mL dry DCM. The peptide 
vessel was removed from inert conditions and allowed to react for 30 minutes. The resin 
was thoroughly rinsed with dichloromethane and subsequently dried by passing air over 
the resin. The dried resin was weighed and 10% of the total resin was transferred to a new 
peptide vessel to couple to the NIR dye. The lysine free amine was coupled to sulfo-
cyanine5 NHS ester (1 eq.) using 50 µL of DIPEA in 0.5 mL of DMF. The peptide vessel 
was covered in foil and allowed to vortex overnight. The resin was thoroughly washed 
with DMF and dichloromethane. 
Full deprotection and cleavage from solid support was performed by adding a 1 mL 
mixture of 95% TFA, 2.5% TIS and 2.5% water to the resin and allowed it to mix for 5 
hours in the dark. The cleaved peptide was precipitated from solution using ice-cold tert-
butyl methyl ether (TBME) and centrifuged (3000 rpm, 10 minutes) resulting in a crude 
peptide pellet. The supernatant was decanted and the resulting peptide pellet was 
dissolved in 20% acetonitrile in water, frozen at -78 °C and lyophilized to a blue crude 
powder. Purification was performed using preparative HPLC-MS and purity of the 
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resulting peptides were analyzed using analytical UHPLC. HRMS (ESI+): m/z calculated 
for C91H131N15O23S2, [M+2H]2+ = 934.4612, observed [M+2H]2+ = 934.1838. 
4.4.3 Automated Peptide Synthesis of 4.10 
Automated peptide synthesis was carried out using Biotage Syrowave and all amino acids 
contained standard protecting groups with the exception of Dpr and Lys that contained 
methyltrityl (Mtt) and allyloxycarbonyl (Alloc) orthogonal protecting groups, 
respectively. The N-terminal glycine contained a BOC protecting group rather than 
Fmoc. 4.10 was synthesized at a 0.1 mmol scale on Rink Amide MBHA resin (0.52 
mmol/g). The resin was initially swelled with N,N-dimethylformamide (DMF) followed 
by two cycles (10 minutes, 5 minutes) of Fmoc deprotection using 2 mL of 20% 
piperidine in N,N-dimethylformamide (DMF). Amino acids were preactivated by 
combining 3 eq. of Fmoc-protected amino acid, 3 eq. of HCTU and 6 eq. of N,N-
diisopropylethylamine (DIPEA) in 2 mL of DMF. The mixture was added to the resin 
and coupled for 60 minutes. These cycles were repeated until all 10 N-terminal amino 
acids were coupled to the resin in the following sequence; H-GS-Dpr(mtt)-Nal-1-LSPT-
AEEA-Lys(Alloc)-Rink Amide MBHA Resin. 
Allyloxycarbonyl deprotection of lysine was performed under inert atmospheric N2 
conditions. DCM was dried over sieves for 24 hours before adding 1 mL to the resin. 2 
eq. of phenylsilane in 1 mL dry DCM was then added to the peptide resin followed by 
0.045 eq. of tetrakis(triphenylphosphine) palladium (0) in 1 mL dry DCM. The peptide 
vessel was removed from inert conditions and allowed to react for 30 minutes. The resin 
was thoroughly washed with dichloromethane and DMF before being manually coupled 
to Fmoc-Lys(alloc)-OH (3 eq.) using HCTU (3 eq.) and DIPEA (6 eq.) in 2 mL of DMF. 
The resin was vortexed for 1 hour and thoroughly rinsed with DMF before being placed 
on the Biotage Syrowave to continue the automated synthesis of the second ghrelin unit 
of the dimer. Upon completion of automated synthesis, the second Dpr(Mtt) was 
deprotected using the same Mtt deprotection protocol explained above and couple to 
octanoic acid using the same coupling conditions. The second Lys(alloc) was deprotected 
using the same method listed above and thoroughly rinsed with dichloromethane before 
drying the resin by passing air over it. The resin was also weighed and 10% of the resin 
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was transferred to a new peptide vessel. The free amine was coupled to sulfo-cyanine5 
NHS ester (Lumiprobe, 1 eq.) with 200 µL of DIPEA in 1 mL of DMF. The resin was 
vortexed in the dark overnight before being thoroughly rinsed with DMF and 
dichloromethane.  
Full deprotection and cleavage from solid support was performed by adding a 1 mL 
mixture of 95% TFA, 2.5% TIS and 2.5% water to the resin and allowed it to mix for 5 
hours in the dark. The cleaved peptide was precipitated from solution using ice-cold tert-
butyl methyl ether (TBME) and centrifuged (3000 rpm, 10 minutes) resulting in a crude 
peptide pellet. The supernatant was decanted and the resulting peptide pellet was 
dissolved in 20% acetonitrile in water, frozen at -78 °C and lyophilized to a blue crude 
powder. Purification was performed using preparative HPLC-MS and purity of the 
resulting peptides were analyzed using analytical UHPLC. HRMS (ESI+): m/z calculated 
for C150H233N27O39S2, [M+2H]2+ = 1547.3027, observed [M+2H]2+ = 1547.9197. 
4.4.4 Competitive Binding Assay (IC50) 
The affinity for GHS-R1a was determined using a radioligand competitive binding assay. 
Assays were performed using GHS-R1a transfected HEK293 cells as receptor source and 
human [125I]-ghrelin(1-28)  (PerkinElmer Inc.) as the radioligand. Human ghrelin(1-28) 
was used as reference to ensure the validity of the results. A suspension of membrane 
from HEK293/GHS-R1a cells (50,000 cells per assay tube) were incubated with 
ghrelin(1-8) peptide analogues (at concentrations of 10-5 M, 10-6 M, 10-7 M, 10-8 M, 10-9 
M, 10-10 M and 10-11 M) and [125I]-ghrelin (15 pM per assay tube) in binding buffer (25 
mM HEPES, 5 mM magnesium chloride, 1 mM calcium chloride, 2.5 mM EDTA, and 
0.4% BSA, pH 7.4). The resulting suspension was incubated for 20 minutes under 
shaking (550 rpm) at 37 °C. Unbound [125I]-ghrelin was removed and the amount of 
[125I]-ghrelin bound to the membranes was measured by Gamma counter. IC50 values 
were determined by nonlinear regression analysis to fit a 4 parameter dose response curve 
using GraphPad Prism 6 (Version 6.0c). All binding assays were performed in triplicate. 
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4.4.5 Fluorescence Microscopy of 4.4 and 4.10 with GHS-R1a 
Monomer 4.4 and dimer 4.10 were dissolved in DMSO for a concentration of 1 mM.  
Dye stocks were subsequently diluted in serum-free Dulbecco's modified Eagle's medium 
media (DMEM) supplemented with Penicillin-Streptomycin (Pen-Strep) to a final 
concentration of 0.5 µM.   
Affinity of dye-labelled peptide was tested towards HT1080 fibrosarcoma cells (ATCC) 
and HT1080 fibrosarcoma cells stably transfected with GHS-R, transcript variant 1a 
(OriGene Technologies Inc.). HT1080 and HT1080/GHSR1a cell lines were seeded onto 
coverslips at 50,000 cells per well in a 12-well plate format.  Cells were incubated 
overnight in DMEM supplemented with 10% fetal bovine serum (FBS) and Pen-Strep at 
37 °C in a 5% CO2 atmosphere.  Media was removed and cells washed once with serum-
free media and twice with phosphate buffer saline (PBS).  Cells were then incubated with 
1 mL of 0.5 µM 4.4 or 4.10 in serum-free media for 1 hour at 37°C in a 5% CO2 
atmosphere.  Cells were washed once with serum free media and twice with phosphate 
buffer saline (PBS), fixed with 4% paraformaldehyde for 15 minutes and mounted onto 
slides containing Pro-Long Antifade® mounting medium with 4',6-diamino-2-
phenylindole (DAPI).  Images were obtained using a Nikon A1R confocal microscope.  
4.4 and 4.10 were visualized with excitation at 636 nm and emission collected between 
663−738 nm.  DAPI was visualized with excitation at 402 nm and emission collected 
between 425-475 nm. 
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Chapter 5 
5 Conclusions 
5.1 Outlook and Conclusions 
This thesis provides an example of how a natural receptor-ligand complex can be 
exploited for diagnostic and therapeutic purposes. Ghrelin, being the endogenous ligand 
for GHS-R1a, provided a high affinity template to begin modifying, as well as a “gold-
standard” to compare the success of other ghrelin analogues.1 The modifications to 
ghrelin were made rationally based off previous ghrelin literature and used classical 
approaches to increasing in vivo affinity and stability, as well as standard approaches to 
incorporating signaling sources, such as optical dyes and radionuclides. The methods led 
to various ghrelin analogues with high affinity to GHS-R1a and only a few were further 
evaluated as optical or scintigraphical imaging agents. The lead analogues are 
summarized in table 5.1 
Table 5.1 Summary of all ghrelin analogues synthesized and the corresponding IC50. 
Chapter Ghrelin Analogue IC50 (nM) 
2 Dpr3(octanoyl), Lys19([69/71Ga]-DOTA)-Ghrelin(1-19) 5.67 
3 Inp1,Dpr3(6-fluoro-2-napthyl),Nal-14,Thr8-Ghrelin(1-8) 0.16 
4 Dpr3(octanoyl), Nal-14, Thr8, AEEA9,Lys10-Ghrelin(1-10)monomer 25.3 
4 Dpr3(octanoyl), Nal-14, Thr8, AEEA9,Lys10-Ghrelin(1-10)dimer 50.0 
The first generation ghrelin analogue, [Dpr3(octanoyl), Lys19(68Ga-DOTA)]-ghrelin(1-19) 
(2.3d), was capable of targeting GHS-R1a with similar affinity to ghrelin(1-28) when 
chelated to gallium-68 and was shown to selectively target GHS-R1a in blocking studies. 
While 2.3d was capable imaging GHS-R1a in vivo, preclinical studies in HT1080 and 
HT1080/GHS-R1a raised two concerns; relatively low localization to the tumour and 
retention of the radioactivity in kidneys. While this analogue supported the capability of 
ghrelin to be used as an in vivo PET imaging agent, there were modifications required to 
provide sufficient tumour uptake, optimal tumour-to-background ratios and overall 
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improved pharmacokinetics. These findings further developed this thesis into the second 
generation of ghrelin(1-8) analogues. 
In an effort positively affect the pharmacokinetic properties of the next generation of 
ghrelin analogues, many of the C-terminal amino acids were removed. This would 
hypothetically remove many amino acid side chain charges and decrease retention in the 
kidneys. Unfortunately, this would also have a detrimental effect on binding affinity. 
Systematic modifications were made to residues 1, 3, 4 and 8 in order to optimize ligand-
receptor interactions and increase binding affinity to GHS-R1a. Various substitutions of 
natural and unnatural amino acids at these residues successfully resulted in many 
ghrelin(1-8) analogues with equal or better binding affinity to GHS-R1a. This also 
introduced an unnatural element to ghrelin(1-8) useful for increasing in vivo stability. 
This generation of analogues was developed with fluorine-bearing side chain 
modification at residue 3 to allow translation to a fluorine-18 imaging agent. New 
radiochemical procedures were devised for the prosthetic group [18F]-PFPN and through 
synthesis of an active ester, [18F]-PFPN was successfully coupled to the lead ghrelin(1-8) 
analogue, H-Inp-S-Dpr-Nal-1-LSPT-NH2, This new ghrelin(1-8) fluorine-18 imaging 
agent ([18F]-3.7) was obtained in 3.6% d.c. yield. The high specificity to GHS-R1a is an 
exciting discovery and preclinical studies are still required to determine if these 
modifications had a positive affect kidney retention, in vivo stability and overall 
pharmacokinetics. 
The final chapter investigated a new approach to optimizing in vivo pharmacokinetics of 
pepetide-based targeting entities by employing multimerization. Other well-studied 
targeting peptides, such as RGD and bombesin resulted in better binding affinity and in 
vivo biodistribution profiles when dimeric and tetrameric peptides were compared to the 
monomeric counterparts.2, 3 Two dye labelled ghrelin analogues, a monomer (4.4) and a 
dimer (4.10), were synthesized to determine if the same trend resulted from 
multimerization of ghrelin. Adding a second unit resulted in a negative effect on binding 
affinity and in vitro properties. Upon dimerization, 4.10 showed non-preferential binding 
in both of the studied cell lines and in turn, is not able to differentiate between GHS-R1a 
expression levels. These results should not deter those from developing different 
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dimerized ghrelin analogues as slight modifications to the structures will affect the 
biological properties.4 An extensive look into 10 amino acid sequence and employing the 
methods mentioned in Chapter 1.4 could result in a more effective ghrelin dimer. It 
would be advantageous to investigate the chain length between ghrelin units by 
synthesizing longer linkers, and using variations of hydrophilic and hydrophobic linkers.5 
It would also be beneficial to study other multimer types of ghrelin such as trimer and 
tetramer analogues as the most successful of the RGD multimers is an octamer.2 The 
positioning of the signaling source at the end of the lysine chain makes it easy to 
investigate other optical dyes, or to incorporate radiometals via chelators or other 
radionuclides using prosthetic group or direct group labeling.  
Previous to the research stated in this thesis, little work had been done on the synthesis of 
ghrelin analogues as PET or SPECT imaging agents. In 2009, non-radioactive ghrelin (1-
5) and ghrelin(1-14) analogues were synthesized to explore whether or not ghrelin was 
capable of tolerating fluorine and rhenium modifications to residue 3. The ghrelin(1-14) 
analogues set the stage for PET imaging potential with ghrelin, but were not further 
developed.6 In 2014, a ghrelin(1-6) peptide was labelled with monodentate and tridentate 
technetium-99m complexes. These peptides had respectable IC50 values of 45 nM and 54 
nM for GHS-R1a but biodistribution studies revealed that this analogue mainly localized 
to the kidneys.7 The research in this thesis extended the knowledge of long and short 
ghrelin analogues as PET imaging agents that was an area previous under studied. It 
provides solid ground work for others to continue optimizing ghrelin in order to improve 
pharmacokinetic properties and design a strong diagnostic and therapeutic peptide 
molecular imaging probe.  
When drawing similarities between the works, it must be noted that ghrelin has shown 
undesirable biodistribution profiles independent of the ghrelin length. As mentioned in 
the introductory material, kidney uptake can be reduced by co-administering megalin or a 
cationic amino acid, but these approaches do not address the issue with the peptide 
targeting entity directly. There is a particular characteristic about ghrelin analogues that 
causes this phenomenon. It would be interesting to use combinatorial methods, such as 
one-bead-one-compound, to synthesize a large library of unrelated peptide sequences that 
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could retain affinity to GHS-R1a without the attraction to kidney.8 These types of 
combinatorial libraries have become more sophisticated and are able to incorporate non-
radioactive counterparts to common radionuclides in order to create a targeting entity that 
requires the signaling source for affinity to the receptor, much like the analogues 
synthesized in Chapter 3.9  
There is another family of peptides that are well-known for targeting GHS-R1a that are 
structurally different to natural ghrelin. The discovery of these peptides began with 
enkephalin (H-TGGFM-OH) in 1977 and through the work of many research groups, 
resulted in many more analogues synthesized by 1995.10-14 These small synthetic peptides 
were capable of releasing growth hormone in in vivo studies and were grouped into a 
family known as growth hormone secretagogues. It was this family of peptides that 
helped lead to the discovery of the receptor GHS-R1a in 1996.15 These peptides already 
have good affinity for GHS-R1a and would not require optimization by truncation. Using 
the classical methods to optimize peptide sequences detailed in Chapter 1, these peptides 
could also targeting GHS-R1a with the affinity that the synthesized truncated ghrelin 
analogues are capable of. Incorporating a molecular imaging signaling source, such as a 
radioisotope or optical dye, could result in larger scope of peptides capable of imaging 
GHS-R1a using imaging modalities. There is value in finding other peptide analogues 
capable of targeting GHS-R1a to determine what is the most reliable method for 
detection.  
Overall, this thesis delved into the versatility of ghrelin and its ability to target its 
endogenous receptor, GHS-R1a. In vitro and in vivo assays clearly demonstrate that 
ghrelin is able to tolerate substantial truncations to the C-terminal region of the natural 
amino acid sequence and using well-known approaches to modifying peptides, varying 
lengths of ghrelin analogues effectively targeted GHS-R1a. Although more research is 
required to validate all these peptides, it is evident they hold potential to be effective 
imaging agents for the various conditions and diseases that are regulated by GHS-R1a 
expression. 
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6 Appendix 
6.1 Chapter 2 HPLC Traces 
HPLC of 2.3d: Analytical 20 – 60 % acetonitrile in water - 15 minutes 
 
HPLC of [69/71Ga]-2.3d: Analytical 30 – 80 % acetonitrile in water - 15 minutes 
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6.2 Chapter 3 HPLC Traces 
HPLC for 3.3: Analytical 30 – 90 % acetonitrile in water – 15 minutes 
 
HPLC for 3.3b: Analytical 20 – 80 % acetonitrile in water – 15 minutes 
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HPLC for 3.3d: Analytical 30 – 90 % acetonitrile in water – 15 minutes 
 
HPLC for 3.3e: Analytical 30 – 90 % acetonitrile in water – 15 minutes 
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HPLC for 3.3f: Analytical 30 – 90 % acetonitrile in water – 15 minutes 
 
HPLC for 3.3g: Analytical 30 – 90 % acetonitrile in water – 15 minutes 
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A
U
4.0e-1
5.0e-1
6.0e-1
7.0e-1
8.0e-1
9.0e-1
1.0
1.1
1.2
1.3
1.4
1.5
1.6
1.7
1.8
AH-01-93-3_QC1_30to90_15min_Sunfire2 2: Diode Array 
Range: 1.647.37
13.04
11.71
8.05
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UHPLC for 3.3h: Analytical 10 – 60 % acetonitrile in water – 4 minutes 
 
HPLC for 3.3i: Analytical 10 – 60 % acetonitrile in water – 4 minutes 
 
 
 
 
 
Time
0.00 0.25 0.50 0.75 1.00 1.25 1.50 1.75 2.00 2.25 2.50 2.75 3.00 3.25 3.50 3.75 4.00
AU
-1.0e+1
-5.0
0.0
5.0
1.0e+1
1.5e+1
2.0e+1
2.5e+1
3.0e+1
3.5e+1
4.0e+1
4.5e+1
CC-06-099-dThr-F5-10to60 3: Diode Array 
Range: 6.111e+11.79
Time
0.00 0.25 0.50 0.75 1.00 1.25 1.50 1.75 2.00 2.25 2.50 2.75 3.00 3.25 3.50 3.75 4.00
AU
-1.0e+1
-5.0
0.0
5.0
1.0e+1
1.5e+1
2.0e+1
2.5e+1
3.0e+1
3.5e+1
4.0e+1
4.5e+1
CC-06-099-BHT-F5-10to60 3: Diode Array 
Range: 5.981e+11.76
93 
 
 
HPLC for 3.3j: Analytical 20 – 80 % acetonitrile in water – 15 minutes 
 
HPLC for 3.4c: Analytical 10 – 60 % acetonitrile in water – 15 minutes 
 
 
 
 
 
Time
0.00 0.25 0.50 0.75 1.00 1.25 1.50 1.75 2.00 2.25 2.50 2.75 3.00 3.25 3.50 3.75 4.00
A
U
0.0
2.0e+1
4.0e+1
6.0e+1
8.0e+1
1.0e+2
1.2e+2
1.4e+2
1.6e+2
1.8e+2
CC-06-041-QC11_10to60 3: Diode Array 
Range: 1.909e+21.91
94 
 
 
HPLC for 3.5a: Analytical 32 – 70 % acetonitrile in water – 15 minutes 
 
HPLC for 3.5c: Analytical 32 – 80% acetonitrile in water – 15 minutes 
 
 
 
 
 
Time
4.00 6.00 8.00 10.00
A
U
0.0
2.5
5.0
7.5
AH-01-51_QC#4_32to70_15min_sunfire_rerun 2: Diode Array 
Range: 8.3256.11
Time
2.00 4.00 6.00 8.00 10.00 12.00 14.00
AU
0.0
5.0e-2
1.0e-1
1.5e-1
2.0e-1
2.5e-1
3.0e-1
3.5e-1
4.0e-1
4.5e-1
5.0e-1
5.5e-1
6.0e-1
6.5e-1
7.0e-1
7.5e-1
8.0e-1
AH-01-079_QC#2_32to80_15min_Atlantis Diode Array 
Range: 8.621e-16.00
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UHPLC for 3.6a: Analytical 10 – 60 % - 4 minutes 
 
UHPLC for 3.6b: Analytical 20 – 70 % - 4 minutes 
 
 
 
Time
-0.00 0.25 0.50 0.75 1.00 1.25 1.50 1.75 2.00 2.25 2.50 2.75 3.00 3.25 3.50 3.75 4.00
AU
-1.5e+1
-1.0e+1
-5.0
0.0
5.0
1.0e+1
1.5e+1
2.0e+1
2.5e+1
3.0e+1
3.5e+1
4.0e+1
4.5e+1
5.0e+1
5.5e+1
6.0e+1
6.5e+1
7.0e+1
7.5e+1
CC-08-007-1-25 4: Diode Array 
Range: 9.235e+12.07
Time
-0.00 0.25 0.50 0.75 1.00 1.25 1.50 1.75 2.00 2.25 2.50 2.75 3.00 3.25 3.50 3.75 4.00
AU
-1.5e+1
-1.0e+1
-5.0
0.0
5.0
1.0e+1
1.5e+1
2.0e+1
2.5e+1
3.0e+1
3.5e+1
4.0e+1
4.5e+1
5.0e+1
5.5e+1
6.0e+1
6.5e+1
CC-08-007-2-24 4: Diode Array 
Range: 8.095e+12.13
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UHPLC for 3.7: Analytical 20 – 70 % - 4 minutes 
 
UHPLC for 3.17: Analytical 10 – 60 % - 4 minutes 
 
 
 
Time
-0.00 0.25 0.50 0.75 1.00 1.25 1.50 1.75 2.00 2.25 2.50 2.75 3.00 3.25 3.50 3.75 4.00
AU
-1.0e+1
-5.0
0.0
5.0
1.0e+1
1.5e+1
2.0e+1
2.5e+1
3.0e+1
3.5e+1
4.0e+1
4.5e+1
5.0e+1
5.5e+1
6.0e+1
6.5e+1
7.0e+1
7.5e+1
8.0e+1
CC-07-137-C4naphthyl_F34 4: Diode Array 
Range: 9.717e+11.92
3.45
Time
-0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 1.60 1.80 2.00 2.20 2.40 2.60 2.80
AU
0.0
5.0
1.0e+1
1.5e+1
2.0e+1
2.5e+1
3.0e+1
3.5e+1
4.0e+1
4.5e+1
5.0e+1
5.5e+1
6.0e+1
6.5e+1
CC-08-007-7_10to60 4: Diode Array 
Range: 6.87e+10.94
0.23
0.30
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6.3 Chapter 3 ESI+ Mass Spectrums 
ESI+ Mass Spectrum for 3.3 
 
ESI+ Mass Spectrum for 3.3b 
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ESI+ Mass Spectrum for 3.3d 
 
ESI+ Mass Spectrum for 3.3e 
 
 
 
 
 
 
m/z
300 400 500 600 700 800 900 1000 1100 1200 1300 1400
%
0
100
AH-01-93-2_QC1_30to90_15min_xbridge 170 (3.142) Cm (158:182) 1: Scan ES+ 
1.34e6932.85
1337802
316.28
974030
299.25
448879
617.45
491247
458.45
290380
317.26
144121 449.50125081
504.34
251655
589.46
162380
505.36
80028
704.53
341926
618.46
189247 705.55
146281
933.84
751277
934.86
240701
954.85
193006
955.85
120232
m/z
300 400 500 600 700 800 900 1000 1100 1200 1300 1400
%
0
100
AH-01-93-3_QC1_30to90_15min_Sunfire2 428 (7.911) Cm (416:439) 1: Scan ES+ 
4.18e5946.80
418196
330.23
226130
313.21
87463
285.22
27942
617.42
154363
504.31
68049
331.23
43312 465.4740390
357.24
29533
589.44
49885
573.36
21014
704.49
128244
618.42
64576 705.47
53988
801.64
21791
947.81
210979
948.84
76540
966.10
24447
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ESI+ Mass Spectrum for 3.3f 
 
ESI+ Mass Spectrum for 3.3g 
 
 
 
 
 
m/z
300 400 500 600 700 800 900 1000 1100 1200 1300 1400
%
0
100
AH-01-93-4_QC1_30to90_15min_Sunfire2 453 (8.373) Cm (445:461) 1: Scan ES+ 
7.58e5919.81
757570
451.74
285910303.27
258676
429.07
156230
357.20
50492
379.63
47363
704.56
169958617.44
140978
504.35
80189
452.48
51026
589.45
46139
686.49
106289
618.45
53146
705.54
66979
920.83
419300
921.86
126706
m/z
300 400 500 600 700 800 900 1000 1100 1200 1300 1400
%
0
100
AH-01-93-3_QC1_30to90_15min_Sunfire2 428 (7.911) Cm (416:439) 1: Scan ES+ 
4.18e5946.80
418196
330.23
226130
313.21
87463
285.22
27942
617.42
154363
504.31
68049
331.23
43312 465.4740390
357.24
29533
589.44
49885
573.36
21014
704.49
128244
618.42
64576 705.47
53988
801.64
21791
947.81
210979
948.84
76540
966.10
24447
100 
 
ESI+ Mass Spectrum for 3.3h 
 
ESI+ Mass Spectrum for 3.3i 
 
 
 
 
 
 
m/z
100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
CC-06-099-dThr-F5-10to60 1249 (1.804) Cm (1235:1356) 1: TOF MS ES+ 
2.56e4921.4526
704.3491
617.3341
303.1423
216.1070
119.0850
504.2535
451.2385
357.2073
832.4512
1837.9573
1379.2859
1082.5825
m/z
200 400 600 800 1000 1200 1400 1600 1800 2000 2200 2400 2600 2800
%
0
100
CC-06-099-BHT-F5-10to60 1224 (1.761) Cm (1224:1322) 1: TOF MS ES+ 
2.10e4935.4747
458.7288
317.1509
230.1275
386.7123
617.3184
704.3491
1865.9990
1400.3167
2333.3623
2177.9551
2799.72712489.1567
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ESI+ Mass Spectrum for 3.3j 
 
ESI+ Mass Spectrum for 3.4c 
 
 
 
 
 
 
m/z
200 400 600 800 1000 1200 1400 1600 1800 2000 2200 2400 2600 2800
%
0
100
CC-06-041-QC11_10to60 1310 (1.892) Cm (1301:1440) 1: TOF MS ES+ 
2.61e41053.1082
527.0809
365.0852
776.1219
2105.2983
1579.85621216.1917 2632.2646
2457.3188
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ESI+ Mass Spectrum for 3.5a 
 
ESI+ Mass Spectrum for 3.5c 
 
 
 
 
 
m/z
400 600 800 1000 1200 1400
%
0
100
AH-01-51_QC#4_32to70_15min_sunfire_rerun 329 (6.081) Cm (320:341)
4.31e51055.87
430689
778.57
94239
278.28
92021 691.47
61502 875.67
44611
1056.90
292171
1057.88
112367
1058.88
28206
m/z
400 600 800 1000 1200 1400
%
0
100
AH-01-79_QC#2_32to80_15min_sunfire 348 (6.432) Cm (333:382)
9.20e51041.81
920419
278.27
693841
764.49
471201
746.47
286290365.25
265396
512.92
199663
765.50
211514
861.63
144726
1042.81
584929
1043.81
203072
1044.82
56077
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ESI+ Mass Spectrum for 3.6a 
 
ESI+ Mass Spectrum for 3.6b 
 
 
 
 
m/z
200 400 600 800 1000 1200 1400 1600 1800
%
0
100
CC-08-007-1-25 113 (2.106) Cm (112:116) 1: TOF MS ES+ 
547969.5985
83.0856
485.3444
102.1665
485.8612
486.3783
970.6251
971.6522
m/z
200 400 600 800 1000 1200 1400 1600 1800
%
0
100
CC-08-007-2-24 117 (2.182) Cm (116:120) 1: TOF MS ES+ 
37383.0856
969.5787
485.3444
102.1665
485.8472
486.3643
970.6053
971.6324
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ESI+ Mass Spectrum for 3.7 
 
ESI+ Mass Spectrum for 3.17 
 
 
 
m/z
200 400 600 800 1000 1200 1400 1600 1800
%
0
100
CC-07-137-C4naphthyl_F34 105 (1.959) 1: TOF MS ES+ 
1661069.5098
79.0341
83.0798
535.3320
130.1881
130.2098
157.0887
375.1943
535.8307
536.3444
536.8729
1070.5259
1071.6045
1072.5798
m/z
200 400 600 800 1000 1200 1400 1600 1800
%
0
100
CC-08-007-7_10to60 53 (0.990) Cm (51:57) 1: TOF MS ES+ 
2.06e3449.1926
83.0741
398.7453
449.5554
449.7301
450.0797
897.4143
450.2679
451.1292
898.4399
899.4662
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6.4 Chapter 3 IC50 Curves 
IC50 curve for 3.3 
 
IC50 curve for 3.3b 
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IC50 curve for 3.3c 
 
IC50 curve for 3.3d 
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IC50 curve for 3.3e 
 
IC50 curve for 3.3f 
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IC50 curve for 3.3g 
 
IC50 curve for 3.3h 
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IC50 curve for 3.3i 
 
IC50 curve for 3.3j 
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IC50 curve for 3.4c 
 
IC50 curve for 3.5a 
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IC50 curve for 3.5b 
 
IC50 curve for 3.5c 
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IC50 curve for 3.6a 
 
IC50 curve for 3.6b 
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6.5 Chapter 3 1H NMR 
1H-NMR of 3.4c (4’-FBC) in DMSO 
 
PROTON_01
13.5 13.0 12.5 12.0 11.5 11.0 10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
2.004.132.080.56
7.
30
7.
33
7.
35
7.
77
7.
79
7.
80
8.
00
8.
02
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1H-NMR of 3.9 in CDCl3
 
 
 
 
 
 
 
 
 
 
PROTON_CC-07-077-F10-1501
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
3.332.001.920.981.000.980.94
CHLOROFORM-d
1.
26
1.
42
1.
43
1.
45
1.
594.
04
4.
39
4.
41
4.
43
4.
44
6.
97
6.
97
6.
99
7.
00
7.
27
7.
587
.6
1
7.
75
7.
78
7.
95
7.
95
7.
97
7.
97
8.
46
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1H-NMR of 3.10 in DMSO 
 
 
 
 
 
 
 
 
 
PROTON_01
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
2.776.001.981.010.982.910.87
DMSO-d6
DMSO 1.
33
1.
34
1.
36
3.
06
3.
344.
30
4.
31
4.
33
4.
356.
95
6.
96
7.
26
7.
27
7.
29
7.
297.
687
.7
1
7.
79
7.
817
.9
0
7.
938.
40
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1H-NMR of 3.11 in DMSO 
 
 
 
 
 
 
 
 
 
PROTON_01
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
2.759.001.980.842.021.011.030.99
DMSO-d6
1.
37
1.
39
1.
40
2.
50
2.
50
3.
36
3.
72
4.
38
4.
40
4.
41
4.
438
.1
7
8.
188.
22
8.
24
8.
268
.4
6
8.
498.
62
8.
638.
77
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H-NMR of 3.13 in CDCl3 
 
 
 
 
 
 
 
 
 
PROTON_CC-08-02101
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
1.001.001.081.071.020.99
CHLOROFORM-d
7.
277.
38
7.
38
7.
40
7.
41
7.
43
7.
54
7.
57
7.
57
7.
92
7.
94
8.
018.
03
8.
04
8.
05
8.
18
8.
20
8.
81
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6.6 Chapter 4 UHPLC Traces 
UHPLC for 4.4: Analytical 10 – 60 % acetonitrile in water – 4 minutes 
 
UHPLC for 4.10: Analytical 10 – 60 % acetonitrile in water – 4 minutes 
 
 
Time
-0.00 0.25 0.50 0.75 1.00 1.25 1.50 1.75 2.00 2.25 2.50 2.75 3.00 3.25 3.50 3.75
AU
-1.6e+1
-1.4e+1
-1.2e+1
-1.0e+1
-8.0
-6.0
-4.0
-2.0
-7.5e-7
2.0
4.0
6.0
8.0
1.0e+1
1.2e+1
CC-08-023-Cy5-F14B 4: Diode Array 
Range: 3.038e+10.26
0.32
1.81
Time
-0.00 0.25 0.50 0.75 1.00 1.25 1.50 1.75 2.00 2.25 2.50 2.75 3.00 3.25 3.50 3.75
AU
-2.0e+1
-1.5e+1
-1.0e+1
-5.0
0.0
5.0
1.0e+1
1.5e+1
2.0e+1
2.5e+1
3.0e+1
CC-08-031-F29 4: Diode Array 
Range: 5.33e+12.41
0.25
0.32
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6.7 Chapter 4 ESI+ Mass Spectrums 
ESI+ Mass Spectrum for 4.4 
 
ESI+ Mass Spectrum for 4.10 
 
m/z
450 500 550 600 650 700 750 800 850 900 950 1000 1050 1100 1150 1200 1250 1300
%
0
100
CC-08-023-Cy5-F14B 99 (1.845) 1: TOF MS ES+ 
19621.9839
622.4899
623.0118
623.4866
652.9161
m/z
700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
CC-08-031-F29 132 (2.461) 1: TOF MS ES+ 
21547.8948
1546.87261032.3191 1569.8425
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